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ABSTRACT
Background: There is growing evidence of association between diabetes and cancer. No 
studies have been conducted in India evaluating this association. With the current 
epidemiologic, nutritional and economic transition in India, it becomes extremely 
important to examine this association in an Indian population. Additionally, difference in 
association exists based on different cancer subtypes. Research has shown that diabetes is 
associated with an increased risk of colorectal cancer. However most of these studies 
suggest detection bias to be one of the probable reasons for this association. Additionally, 
the common risk factors shared by both these conditions are considered to one of the 
reasons in the association. Furthermore, very few studies have assessed the association 
between duration of diabetes and either CRC risk or disease aggressiveness. Even more 
rarely have studies confirmed the status of type 2 diabetes mellitus (T2DM) while 
determining the diabetes-CRC association. 
Methods: For our first objective, we used the Mumbai Cohort Study (MCS)- a 
longitudinal study. Diabetes information was collected at baseline and cancer information 
was received via follow-up questionnaire and confirmed using cancer registry. We also 
evaluated the association between diabetes and cancer subtypes after creating matched 
datasets for each cancer subtype. We used Cox Proportional model for cancer incidence 
and conditional logistic regression for cancer subtypes. For our second and third question, 
we used the Prostate Lung Colorectal Ovarian (PLCO) Cancer screening trial. Diabetes 
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information was self-reported and collected at baseline and using one of the follow-up 
questionnaires-supplemental questionnaires. The cancer information was collected using 
annual survey questionnaire (ASU) administered every year and confirmed using medical 
records. For our second aim final analysis we use cox proportional hazards model. To 
evaluate the notion of detection bias, we conducted stratified analysis. In our final 
question, the diabetes duration was calculated using information on age at diabetes 
diagnosis. We fit a Cox proportional hazards model for cancer incidence and conducted 
logistic regression analysis for cancer grade and stage. 
Results: In the MCS, we did not observe any significant associations between diabetes 
and all cancer incidence and cancer subgroups. However the association was in the 
expected direction. The hazards of all cancer incidence was 1.06 (95%CI=0.75, 1.62) 
among persons with diabetes as compared to people without diabetes. Among cancer 
subtypes, there was an increased risk of ‘lip/oral/pharyngeal cancer’ (OR=1.83; 
95%CI=0.86, 3.86) and ‘respiratory tract cancer’ among people with diabetes (OR=1.28; 
95%CI=0.53, 3.13) respectively.  Inverse direction was observed for ‘digestive organ 
cancer and ‘breast/prostate/uterine/cervical cancer’ among people with diabetes 
compared to people without diabetes (OR=0.59; 95%CI=0.27, 1.32) and (OR=0.66; 
95%CI=0.24, 1.84) respectively, but none of these associations reached statistical 
significance. For our second aim, we observed a 33% higher risk of CRC among people 
with diabetes as compared to people without diabetes. After stratifying the results by 
screening arm, we still found a higher risk among both the screening arms, (HR=1.41, 
95%CI=1.13, 1.76) among the control arm (HR=1.22, 95%CI=0.94, 1.58). After 
stratifying by BMI, the risk was still high among people with diabetes in all the groups. 
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In our final aim, we observed that participants with >10 years of diabetes had a higher 
risk (HR=1.37; 95%CI: 1.06, 1.77) of CRC incidence compared people without diabetes. 
An apparently smaller effect was observed among people with <10 years of diabetes 
duration (HR=1.13; 95%CI: 0.89, 1.43); however, it was not significant. We did not find 
significant results in the association between cancer aggressiveness and diabetes. 
Conclusion: In Indian population, our findings appear to show a higher hazards of all 
cancer incidence, lip/oral/pharyngeal and respiratory tract cancer among people with 
diabetes compared to people without diabetes. They direction of the association is 
consistent with previous study results. However the association is not significant. Future 
studies needed to explore this association in detail. Secondly, in the PLCO data, our 
findings showed an association between diabetes and increased risk of colorectal cancer. 
Detection might not be the reason for this association. Further studies should include 
information on other factors like diabetic medications. For our final aim, the CRC risk 




Dedication .......................................................................................................................... iii 
Acknowledgements ............................................................................................................ iv 
Abstract .............................................................................................................................. vi 
List of Tables ..................................................................................................................... xi 
List of Figures ................................................................................................................... xii 
List of Abbreviations ....................................................................................................... xiii 
Chapter 1: Introduction ........................................................................................................1 
                  Statement of Problem .........................................................................................1 
                  Purpose and Objective .......................................................................................4 
                  Significance of Research ...................................................................................7 
                  Study Outline .....................................................................................................9 
Chapter 2 Background and Significance............................................................................10 
                   Cancer Statistics ..............................................................................................10 
                   Risk Factors in relation to Colorectal Cancer .................................................11 
                   Diabetes and Colorectal Cancer Risk .............................................................13 
                   Purpose of the Study .......................................................................................17 
                   Addressing the existing gaps ..........................................................................17 
Chapter 3 Methods .............................................................................................................20 
                   Introduction .....................................................................................................20 
                   Database Used .................................................................................................20 
x 
                   AIM 1 ..............................................................................................................22 
                   AIM 2 ..............................................................................................................25 
                   AIM 3 ..............................................................................................................28 
Chapter 4 Association between Diabetes Mellitus and Cancer and Cancer Subtypes In 
Indian Population ...............................................................................................................33 
                   Abstract ...........................................................................................................33 
          Introduction .....................................................................................................35 
                   Methods...........................................................................................................36 
                   Results .............................................................................................................40 
                   Discussion .......................................................................................................41 
Chapter 5 Association between Diabetes and Colorectal Cancer Incidence- A 
Longitudinal Study in the US Population ..........................................................................49 
          Abstract ...........................................................................................................49 
          Introduction .....................................................................................................51 
                   Methods...........................................................................................................52 
                   Results .............................................................................................................56 
                   Discussion .......................................................................................................57 
Chapter 6 Duration of Diabetes and Colorectal Cancer Incidence – In a Longitudinal 
Study ..................................................................................................................................69 
                   Abstract ...........................................................................................................69 
          Introduction .....................................................................................................71 
                   Methods...........................................................................................................72 
                   Results .............................................................................................................76 
                   Discussion .......................................................................................................77 




Table 4.1 Descriptive Statistics for the overall population by diabetes mellitus status, 
Mumbai Cohort Study, Mumbai Maharashtra, 1991-2003 ................................................43 
 
Table 4.2 Unadjusted model - HR (95%CI) for all cancer incidence by diabetes mellitus, 
Mumbai Cohort Study, Mumbai Maharashtra, 1991-2003 ................................................44 
 
Table 4.3 Distribution of cancer subtypes across four categories of cancer, Mumbai 
Cohort Study, Mumbai Maharashtra, 1991-2003 ..............................................................45 
 
Table 4.4 Conditional OR (95%CI) for cancer subtypes in relation to diabetes mellitus, 
Mumbai Cohort Study, Mumbai Maharashtra, 1991-2003 ................................................46 
 
Table 5.1 Descriptive statistics of the PLCO population by diabetes status .....................60 
Table 5.2 Unadjusted HR (95%CI) for CRC by diabetes ..................................................62 
Table 5.3 Adjusted model with HR (95%CI) for CRC by diabetes...................................62
Table 5.4 Adjusted model with HR (95%CI) for CRC by diabetes...................................63
Table 5.5 HR (95% CI) for CRC in relation to diabetes stratified by screening arm ........64
Table 5.6 Adjusted model with HR (95%CI), stratified by BMI .......................................65
Table 5.7 Adjusted model with HR (95%CI), stratified by BMI including diet data ........66
Table 6.1 Descriptive statistics by diabetes duration, PLCO, 1993 to 2009 .....................80
Table 6.2 HR (95%CI) for CRC incidence by diabetes duration, PLCO, 1993 to 2009 ...82
Table 6.3 OR (95%CI) for cancer aggressiveness – stage by duration of diabetes ...........82
Table 6.4 OR (95%CI) for cancer aggressiveness – grade by duration of diabetes ..........82
xii 
LIST OF FIGURES
Figure 5.1 Consort diagram for the final analytic dataset ..................................................59 
Figure 6.1 Sample size used for calculating the diabetes duration ....................................78 
Figure 6.2 Consort diagram for final analytic dataset, PLCO, 1993 to 2009 ....................79 
xiii 
LIST OF ABBREVIATIONS
ADA .................................................................................... American Diabetes Association 
BMI ........................................................................................................... Body Mass Index 
CDC ................................................................................................ Early Treatment Failure 
CRC...........................................................................................................Colorectal Cancer 
DII ............................................................................................ Dietary Inflammatory Index 
HDI ............................................................................................... High Development Index 
ICD ........................................................................... International Classification of Disease 
IGF-I ........................................................................................ Insulin-like Growth Factor-I 
MCS ...................................................................................................Mumbai Cohort Study 
PLCO ............................................................................... Prostate Lung Colorectal Ovarian 
SEER ............................................................. Surveillance, Epidemiology, and End Results 




Statement of Problem: 
Type 2 Diabetes Mellitus (T2DM) and cancer are both among the top 10 leading 
causes of mortality (1-3). Though to differing extents, both of these diseases can be 
prevented and controlled by appropriate healthy lifestyle and behavioral changes.  
Cancer is a major public health problem and has been studied in many different 
populations worldwide; however, the incidence, mortality and therefore prevalence of 
different types of cancer varies across these populations (1, 4). Traditionally, cancer has 
been considered to be a disease of more developed countries; i.e., those with high 
development index (HDI). However, recently there has been a change in the trend of 
these diseases. A decrease in colorectal cancer incidence was observed in the US based 
on the SEER data (4).   
Many developing countries are now experiencing increasing rates of “diseases of 
affluence” such as cancer and diabetes, while existing communicable diseases also 
present a public health problem (5-10). Some of these countries’ relatively low cancer 
rates might reflect deficiencies in existing country-wide surveillance systems. Also, the 
developing world is going through an economic and nutrition transition with increased 
urbanization and changing lifestyle factors, including poor diet, sedentary lifestyles, and 
2 
 
increased stress leading to a rise in rates of chronic diseases such as diabetes, cancer and 
heart diseases (1, 4, 5, 7-9, 11-15).  
It is the one of the commonly diagnosed cancer among both males and females 
(16-18). Based on Globocan estimations worldwide, CRC ranks third among males, and 
second among females (19). Around 1.2 million Americans are living with a diagnosis of 
CRC. There has been a decrease in the incidence of CRC since mid-1980s due to 
identification and removal of adenomatous polyps screening (17). Despite improvements 
in screening techniques; compared to other cancers, incidence and prevalence of CRC 
remains high. CRC remains one of the top 3 causes of cancer deaths in both men and 
women (20). Lung cancer ranks the first in both followed by breast cancer among 
females and prostate cancer among males.  
In 2010, the expenses for cancer care in the United States were around $125 
billion (21, 22). These costs can be reduced by improving access to screening available 
facilities to everyone, educating people about it and improving dietary and lifestyle 
habits. The risk factors linked with CRC include higher age, unhealthy dietary habits, 
physical inactivity, obesity, smoking, alcohol use, personal history of polyps, and family 
history of CRC, (17, 22-27). Studies also have shown that T2DM is associated with 
increased risk of CRC (3, 28-44).  
T2DM is a type of diabetes, characterized by hyperglycemia due to either 
inadequate insulin secretion or its utilization or both. Worldwide, T2DM rates are 
increasing rapidly (45-47). The estimated prevalence of T2DM was 9% in 2014 in 18+ 
years age group, worldwide. In 2012, around 1.5 million deaths were due to T2DM. The 
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prevalence of T2DM is estimated to almost double in 2030 (4.4%) from that observed in 
2000 (2.8%) (46, 47). At the same time, and especially in Asia, T2DM is emerging as an 
epidemic (46-51). 
Diagnosed diabetes accounts for an estimated $245 billion cost to U.S. society 
consisting of $176 billion direct and $69 billion in reduced productivity (52). Besides 
this, chronic long-term diabetes is associated with functional damage of several other 
organs especially kidneys, eyes and organs of the cardiovascular system (53-56).  
Existing research suggest an association between T2DM and cancer (3, 28-30, 33-
35, 37, 39, 41-44, 57-64). Both these diseases place a burden on individual health and the 
nation’s overall health and economic status. Among all the cancers, CRC is the most 
strongly associated with T2DM (57, 58, 60, 64-66). Many known risk factors are 
common to both these diseases; for example, obesity, unhealthy diet and physical 
inactivity (3, 28-30, 33-35, 37-42, 67-74). Various patho-physiological mechanisms have 
been hypothesized to explain the association between T2DM and CRC. Diabetes can 
have an influence on colorectal cancer through these mechanisms: hyperinsulinemia, 
chronic inflammation and hyperglycemia (3, 17, 29, 33, 36, 37, 39, 42, 44, 61, 75, 76). 
Insulin and Insulin-like growth factor (IGF-I) have a proliferative effect of the colonic 
epithelium leading to mutations. Thus insulin plays a role in initiation and progression of 
colon carcinogenesis. Research is even conducted on the diabetic medication use and its 
impact on risk of cancer. Inconsistent findings are seen among users of subcutaneous 
injections of insulin and insulin analogs. Few studies suggest an increased risk especially 
with long-acting drug glargine while some suggest no association (77-81). Insulin 
resistance leads to hyperinsulinemia thus promoting carcinogenesis indirectly (61, 75, 82-
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84). Apart from hyperinsulinemia, chronic low grade inflammation is one of the reasons 
for the association between T2DM and CRC.  (36, 43). Inflammation has also been 
shown to predict development of T2DM (85-90). Elevated levels of inflammatory 
markers; C-reactive protein and IL-6 were observed among diabetics (65, 91-94). 
Inflammatory cytokines like TNF-α, IL-6, stimulate insulin sensitivity, continuing low-
grade inflammation, insulin resistance and thereby playing a role in carcinogenesis (95, 
96).    
Diet and physical activity also are shown to affect insulin levels (61, 67-69, 97-
101). All these factors have pro/anti inflammatory effect on the body depending on the 
adapted lifestyle. Unhealthy diet and low levels of physical activity have a pro-
inflammatory effect on the body (102-112). These factors have also have been shown to 
exert an effect on colorectal carcinogenesis through inflammation-related pathways (113-
121). Thus, it is important to understand this aspect of association.  
Purpose and Objectives 
Several studies have examined the association between CRC and diabetes (3, 28-
44, 61, 76). Most of these studies have been conducted in developed countries, where the 
CRC rates are higher. Not many studies have been conducted in developing countries 
especially in a country such as India, which is currently experiencing dramatic 
demographic, economic, epidemiologic and nutrition transitions (5, 8, 9, 13-15, 122, 
123). Besides this, none of the studies have checked for the role of inflammation through 
diet in this association. Studies including diet as a confounder have focused only on a few 
dietary items such as fruits and vegetables, coffee intake, dairy products, whole grains 
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and red meat consumption.(3, 29, 37, 38, 42, 44, 124, 125) There are dietary items that 
also have been shown to be associated with CRC via its inflammatory effect. Therefore, it 
is important to study this effect, too. Secondly, many previous studies have mentioned the 
possibility of diagnostic bias existing in this association. Through our study, we will try 
to address these gaps in this association.  
With our first objective, we will determine the association between diabetes 
(T2DM) and all cancer incidence in an Indian database (MCS. India is a diverse country 
in terms of religion, culture, and lifestyle behaviors. Currently, diabetes is increasing at 
an alarmingly rate in India (48-50).  Although, compared to Western countries, the cancer 
rates are lower in India; they are still high and are on an increasing trend. Additionally, 
with the current ominous changes in above-mentioned lifestyle factors, it is likely that 
cancer rates will increase. Thus, it becomes important to determine the association 
between diabetes and cancer incidence in India.  
Besides changes in lifestyle factors leading to the increase in chronic disease rates 
the Indian population is more susceptible to metabolic syndrome (126-131). Metabolic 
syndrome is characterized by higher blood pressure, abdominal obesity, abnormal 
cholesterol levels, higher blood sugar, pro-inflammatory state (132). Worldwide, the 
Indian population is shown to be prone to metabolic syndrome and having a higher risk 
of developing T2DM (130). We will evaluate for the potentially confounding effect of 
BMI in this association. Similar to race and ethnicity in the USA, (caste) religion also can 
have an effect on this association as considerable differences exist by religion in the 




In our second objective, we will use Prostate Lung Cancer Ovarian Screening 
Trial – a longitudinal US database to determine the association between T2DM and CRC. 
We will include all of the important potential confounders – including a variety of socio-
demographic variables, BMI, physical activity, and duration of T2DM. Based on the 
literature, it is known that diet and inflammation play an important role in this 
association. Most of the studies focusing on diet have included only few dietary items 
that do not represent a complete measure of diet. In this study, we will include DII that 
calculates the inflammatory score based on total dietary intake. Thereby, we will check 
for impact of inflammation through diet (using the DII) on the association between 
T2DM and CRC incidence. As seen in most of the studies, one of the important biases 
determined in all studies was diagnostic bias; in our project we will include screening as 
one of the confounders. Fortunately, the PLCO is a screening trial and thus has 
information on screening for 4 cancers (prostrate, lung, colorectal and ovarian cancer). 
In our third objective, we will use duration of T2DM as our main exposure and 
examine its effect on CRC incidence, whereby the study will be restricted to participants 
having diabetes at baseline.  We will also explore the association between T2DM 
duration and CRC grade and stage. For this question, we will use the PLCO database. 
Cancer grade is based on the ICD-O-2 (International Classification of Disease for 
Oncology 2
nd
 Edition). In this part of the dissertation we will again determine effect 
modification caused by DII.  
For all our aims involving cancer incidence and time-to-disease as the outcome, 
we will use Cox Proportional Hazards Models.  
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AIM 1: To determine the association between diabetes (T2DM) and all cancer incidence 
in an Indian database (MCS) 
Hypothesis: Participants with T2DM have a higher risk of cancer incidence after 
controlling potential confounders. Religion and BMI also has an impact on this 
association. Additionally, diabetes is also associated with cancer subgroups.  
AIM 2: To determine the association between T2DM and colorectal cancer incidence in 
PLCO screening trial database 
Hypothesis 1: Participants with T2DM have a higher risk of CRC incidence after 
adjusting for potential confounders. 
Hypothesis 2: DII influences the association between T2DM and CRC incidence. 
Hypothesis 3: Screening modifies the association between diabetes and CRC 
AIM 3: To examine the effect of duration of diabetes with colorectal cancer incidence 
and grades and stages of cancer. 
Hypothesis 1: With an increase in the duration of T2DM there is an increased risk of 
CRC incidence. 
Hypothesis 2: With increasing duration of diabetes, a higher stage of CRC is observed.  
Significance of Research:  
Our overall findings will contribute to current knowledge regarding the 
association between T2DM and cancer. With our first aim, we are determining this 
association in India, where no such studies exist. It is important to study this question in a 
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country such as India, because the rates of T2DM are increasing at an alarming rate and it 
is in an epidemiological transition phase. Findings of the study will demonstrate the 
importance of this association and the probable reasons that need to be studied in future 
studies that will inform steps that would need to be taken among diabetics to reduce the 
likelihood of colorectal cancer (and other inflammation -related conditions). An obvious 
strength of this work is that it is a prospective study conducted in Mumbai – a culturally 
diverse and densely populated city. 
In our 2
nd
 aim, we will be studying the association in US database – PLCO - a 
cohort study. This study was a screening trial; therefore, for this study; we will use 
information on screening. This can help in avoiding diagnostic bias that is one of the 
commonest biases many previous studies. Besides that, we will be using DII - a technique 
that quantifies the inflammatory potential of diet. As inflammation plays a vital role in 
this association, utilizing DII provides a new angle to the existing knowledge about diet 
and its role in the association. As both of these diseases have common risk factors, we 
will be controlling for the potential confounders.  
As shown by a few of the previous studies, duration of T2DM also has an impact 
on CRC. As a part of my 3
rd
 aim, we will be looking at the duration of T2DM and its 
impact on CRC incidence, disease grade and stage. Results from this study will help in 
understanding if longer duration of diabetes has an impact on the development, grading 
and staging of CRC. The main exposure used here; i.e., diet-related inflammation, has 
rarely been checked for in the previous studies. Again, in this study we will include DII 
score in our models. Based on the previous literature, it is known that diet has an 
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influence on diabetes.  This dietary effect also may be due to the inflammatory effect of 
diet. Therefore, it is more important to understand this association in greater detail. 
Most of the previous studies have not utilized diet for their analysis and the 
studies including it have only used restricted groups of foods. In our study, including DII 
is innovative and will lead to meaningful improvements in our understanding of 
colorectal carcinogenesis.  
Study Outline  
In Chapter 2, we will provide details on the past studies conducted worldwide 
determining the association between diabetes and CRC. We also will briefly mention 
previous study results providing background and support on the association and the 
factors being controlled. For the Chapter 3, we will provide details on the two databases 
being used in our study, the data collection techniques and our selected analytical 
methods. In chapter 4, we will include our first manuscript based on our first aim, 
followed by Chapter 5 and 6, based on the manuscripts for aim 2 and 3, respectively. 
Chapter 7 will include information on the overall discussions and conclusions for the 
study. In Chapter 7, I also will discuss what I have learned in the process of conducting 
this dissertation research, describe the scope for further research in this area, and provide 





BACKGROUND AND SIGNIFICANCE 
Cancer Statistics 
One of the leading causes of morbidity and mortality worldwide is cancer. The 
estimated number of new cases of cancer is 15 million worldwide. Regional disparities 
exist across different types of cancer and affect population subgroups differentially. 
Colorectal cancer (CRC) is one of the top four cancers seen in both males and females 
(4). Among all cancers, it is the 3
rd
 most common (1, 18).  It is also the fourth leading 
cause of cancer mortality (18). It is well-documented that quality of life is impaired in 
cancer patients, especially after receiving cancer treatment (133-136).  Five-year 
mortality for CRC patients is around 40% (22). There are treatment differences based on 
disease stage and grade. Clearly, this affects associated costs.  
5-10% of CRC cases are due to hereditary causes, but most of the other cases are 
due to modifiable causes (24).   While CRC incidence rates have been high in developed 
countries for some time, an overall increase in CRC incidence rates is observed in low- 
and middle-income countries (1, 7). The CRC rates are also increasing rapidly in Asia, 
especially in Eastern Asia, for example, in countries like China, Japan,  and Singapore a  
two- fourfold increase has been observed in the past few years (10).  Contrary to this,  a 
decrease in the CRC incidence rates is seen in especially the previous high-risk places 
(New Zealand, US and Canada) due to early screening and detection of pre-cancerous 
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polyps(1).  To develop an optimum prevention strategy, it is important to understand the 
risk factors and underlying pathology of the disease in further detail.  
A number of CRC risk factors– modifiable and non-modifiable have been 
identified. For example, CRC is more commonly observed among older age groups. 
People with a personal history of inflammatory bowel disease, diabetes and a family 
history of CRC and or adenomatous polyps are at a higher risk of developing CRC. 
However, there are many risk factors that can be changed to reduce the risk of CRC.  
These include diet, physical activity, smoking, alcohol use and obesity. These risk factors 
are also common for type 2 diabetes.  
Risk factors in relation to Colorectal Cancer 
Physical Activity and Colorectal Cancer 
Many studies have examined this association. It was found that physical inactivity 
is related to increased risk of CRC (61, 74, 118, 119, 137, 138). These results are 
consistent with what is observed worldwide.  Sedentary lifestyle also is associated with 
obesity, which is another risk factor for CRC (38, 73, 139, 140). Besides this, physical 
activity also protects against inflammation and insulin resistance (101-103, 105, 114, 
141), both of which also are linked with T2DM (103). Most of these studies included self 
reported questionnaire data on physical activity. These questionnaires include 




Diet and Colorectal cancer 
Diet is one of the important factors linked with CRC.  Different dietary 
components have differential effects. Inconsistent results have been have been seen 
between red meat intake and risk of CRC (142-144).  However, most of these studies 
have observed an increased risk of CRC with increased intake of red meat (145-147). 
Studies determining effect of fish consumption on CRC also showed mixed results; 
however, most of these studies demonstrated beneficial effects of fish consumption on 
CRC risk (44, 145, 146, 148-150). Dietary fiber, whole foods, and fruit and vegetable 
intake are associated with reduced risk of CRC (113, 117, 151, 152). Literature suggests 
that most of these dietary factors have an impact on CRC risk through inflammation-
related pathways (107). Diets high in total calories and saturated fat and with low levels 
of dietary fiber leads to insulin resistance, which is associated with both T2DM and CRC 
(82). Several types of diets have shown to have distinct effects on risk of CRC and other 
chronic diseases. Western diet is associated with increased inflammation, while 
Mediterranean and Macrobiotic diets are associated with decreased inflammation (106, 
110, 112, 153). Mediterranean diet consists of higher intake of fruits and vegetables, 
olive oil, nuts and seeds (106, 110, 154-158). Macrobiotic diet is based on a high intake 
of vegetables and beans and whole grains and low intake of sweeteners, and fruits (159, 
160). These patterns include components that are linked with lower inflammation, 




Alcohol intake, Smoking and CRC risk 
Alcohol intake may have either a positive or negative effect on CRC risk 
depending on the amount (dose) of intake (23, 27, 38, 138, 168, 169). Higher intake is 
associated with increased risk (38, 138, 168, 169). Most of the studies observed that 
smokers have a higher risk of CRC (26, 170-172).  
Diabetes and CRC risk 
As mentioned earlier, CRC also is considered to be one of the important risk 
factors for CRC. Studies have shown an increased risk of CRC among diabetics (3, 28-
35, 37, 39-44, 61).  
Meta-Analysis and Review Studies  
A meta-analysis by De Bruijin, included 20 studies examining the association 
between T2DM and breast and colorectal cancer risk and mortality, of which 6 
prospective studies had CRC incidence as their main outcome. Results from these studies 
suggest that people with diabetes are at increased risk of CRC compared to non-diabetics 
(31). Shikata et al. in their review study also summarized similar results regarding the 
association (66). People with T2DM are at increased risk of developing and dying from 
CRC. These results are consistent across studies conducted in different geographical 
regions. However not all studies produce consistent information on all the potential risk 
factors including, diet and physical activity. Another meta-analysis conducted by Deng, 
based on studies conducted from 1966 to 2011 included 24 case-control and cohort 
studies (32). This review demonstrated 26% higher risk of CRC among diabetics as 
compared to non-diabetics. On stratifying by study design, an 8% increased risk of CRC 
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was observed in case-control studies compared to cohort studies.. The three important 
confounders having a positive association in the risk between diabetes and CRC risk are 
BMI, physical activity and tobacco use. The review also demonstrated the importance of 
insulin therapy on CRC incidence. The results of another meta-analysis consisting of 25 
studies suggested a strong positive association (37). No significant difference in this 
association was observed between males and females. Higher incidence rates were 
observed among case-control studies than in cohort studies. Besides these reviews and 
meta-analysis, there have been various case-control and cohort studies conducted 
worldwide.  
European Studies / Australian:  
The European studies also suggest an increased risk of CRC among diabetics as 
compared to non-diabetics (29, 37, 76). Some of the studies evaluated the association 
separately for colon and rectal cancer. Most of these studies showed an increased risk of 
colon cancer associated with diabetes; however, mixed results were observed with rectal 
cancer (29, 37, 62, 76). One study, conducted in Scotland, found an increased association 
with colon cancer but detected no association with rectal cancer (62). Some of the studies 
showed an increase risk in both colon and rectal cancer. Physical activity, one of the 
important risk factors, was evaluated by most of these studies and some of these results 
were consistent with the previous literature showing a higher risk associated with low 
physical activity (37, 61). The study by La Vecchia et al. suggested no association with 
leisure-time physical activity (29).  Total energy intake, dietary fiber and fat intake were 
some of the important dietary factors considered in the Italian study, and the results did 
not show any effect modification by diet in this association (29). However, not all studies 
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included information on some of the important confounders. Dietary data were lacking in 
most of these studies except for the study by La Vecchia (29). The retrospective cohort 
study conducted by Yang et al. focused only on insulin therapy (30). Only one study has 
been conducted in Australia that showed an increased risk of colon cancer, higher among 
males compared to females (60). 
American Studies:  
Many studies evaluating this association have been conducted in the US (3, 34, 
44, 84, 124). Although the rates are decreasing, the US still ranks high in sex-specific, 
lung, pancreatic and colorectal cancer rates. Western populations are at a higher risk for 
different cancers especially due to unhealthy lifestyle behaviors. Red meat intake, alcohol 
consumption, low physical activity, and higher smoking rates are some of the factors 
strongly linked with CRC , majorly contributing towards the increase in risk (37, 38, 44, 
61, 74, 113, 118, 119, 137, 138, 145-147, 170-173). However, recent trends suggest 
decrease in the incidence and mortality of CRC (18, 174). This is attributed to the 
improved and timely implementation of screening techniques leading to early detection 
of risk factors and thereby early treatment (59, 125, 175-177).  
Based on our literature search, all US studies have suggested an increased risk of 
CRC in association with T2DM. Studies focusing only on women found results similar to 
those seen in general population; i.e., an increased risk of CRC among diabetics as 
compared to non-diabetics (33, 34, 39). However, some of the studies comparing the 
association between the two sexes, showed a higher risk among males as compared to 
females (39, 41, 42, 57). However, a study by Diaz Algorri et al. no association was 
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detected among men. Subsite specific risk also showed no association in men; however, 
among women it demonstrated a higher risk of proximal colon cancer compared to 
controls (124). Physical activity was controlled in most of the studies (3, 28, 33, 34, 37, 
38, 42, 44). As obesity is one of the important confounders, most of the studies adjusted 
for BMI. Many studies adjusted for diet. However, fruits and vegetables were the only 
items adjusted consistently in most of these studies (28, 33, 37, 38, 44, 84, 124). Some of 
these studies also adjusted for red meat consumption, which is linked with higher risk of 
CRC (28, 33, 34, 44, 124).  
Some studies also considered duration of diabetes and examined its association 
with CRC risk. There was no specific trend observed in the association. Few of the 
studies suggested a stronger association among subjects with increased duration of 
diabetes, while one study showed participants in the intermediate duration of diabetes had 
a stronger association compared to the longest duration and minimum duration diabetics 
(28, 29, 34).  
Asian Studies: 
 There are very few Asian studies assessing the association between T2DM and 
CRC. Most of these studies have been conducted in Japan and China and between the 
years 1988-2003. However, all of these studies showed an increased risk of colon cancer 
among diabetics as compared to non-diabetics. Both studies conducted in Japan were 
cohort designs. The study by M.Inoue consisted information on medical history of major 
diseases, smoking and alcohol habits, BMI, physical activity and food intake frequency 
while the study by Khan et al. included information on history of diabetes, BMI, smoking 
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and drinking habits and other demographic variables only (57, 65). An ecological study 
based on data from 170 countries and a population-based risk analysis was conducted in 
China by X.Ren (41). In this study, a higher risk of colon cancer was observed among 
diabetics. However, no association was found with rectal cancer. An increased risk of 
colon cancer was observed among both males and females in the prospective study 
conducted by Seow et al.(42).  This association remained consistent among individuals 
with high calorie intake and low physical activity. Using stratified analysis, they also 
found an association between diabetes and CRC among people with lower BMI levels 
compared to Western population. In another study conducted in Japanese population by 
Kiyonori et al, strong increased risk of cancer of pancreas among men and stomach, 
colorectum and corpus uteri among females was observed among diabetics (58). Family 
history of diabetes also was associated with an increased cancer risk. High rates were 
observed for colorectal cancer among both men and women. However, due to the case-
control study design, it was difficult to determine the causality in the association.  
Purpose of the study 
As mentioned previously, both T2DM and CRC have common risk factors. In 
evaluating the association between T2DM and CRC, it is important to understand the role 
of, and account for these risk factors that may function as potential confounders. Besides 
obesity, the majority of previous studies have been unable to account for some of the 
important confounders. Diet (dietary factors) and physical activity were controlled for in 
very few studies. Through our study, we want to overcome this limitation and include all 
the available potential confounders and/or effect modifiers important in this association.  
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Addressing the existing gaps 
Diet: Studies examining dietary factors included individual food items and/or dietary 
ingredients. The major dietary factors included in these studies were fruits and vegetable 
and total calorie intake (3, 28, 33, 34, 37, 38, 42, 44, 84, 124). Red meat and dietary fat 
intake also was studied by the authors and it was found to be associated with increased 
risk of CRC in some of these studies (28, 33, 34, 37, 124). However, not all studies 
included important dietary covariates. Most of these dietary factors are associated with 
cancer due to its inflammatory effect on body.  
It is important to understand that overall diet can have differential impact on 
health as compared to individual dietary ingredients. We know that diet, through 
inflammatory pathways, is associated with cancer (115, 116, 120, 165). Inflammation 
also is known to be associated with T2DM (87, 88). Besides this, unhealthy dietary habits 
i.e. diets high in fat, sugar intake and overall consisting of higher pro-inflammatory 
components also are related to obesity which is one of the risk factors for both T2DM and 
cancer. Diet plays a major role in the development and progression of T2DM, too.  
Therefore, in our study we will be utilizing the dietary inflammatory index (DII) - 
a unique tool developed to calculate the overall inflammatory potential of diet. DII scores 
are based on up to 45 food parameters. The index has been validated using different 
methods of dietary data collection (24-hour recalls and 7DDR) (115). Various studies 
using DII have found that higher pro-inflammatory scores are associated with higher risk 
of colorectal cancer (115, 116, 120)  The current ongoing research also has shown that it 
is associated with T2DM (108)  
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Diagnostic Bias: Diagnostic bias was one of the concerns raised in most of the above-
mentioned studies (30, 34, 60). People with diabetes might have a higher probability of 
visiting doctor’s clinic, thereby getting screened for other diseases too. A lot of these 
studies were unable to resolve this bias. For this part of our project, we are using data 
from the Prostate Lung Colorectal Ovarian Cancer Screening Trial (PLCO), a screening 
trial. The PLCO study was conducted to determine if screening tests reduces mortality 
from prostate, lung, colorectal, and ovarian cancer. At the beginning of the study the 
participants were randomized on screening tests for each cancer. We can utilize this 
information on screening and try to address the problem of diagnostic bias. 
Indian Study: Based on the past research conducted in this area, it was observed that no 
studies have been conducted in India. India is a culturally diverse country with lot of 
variations in their overall dietary and lifestyle behavior (14, 178). More than 60% of 
diabetics worldwide are in Asia, of which around 50% are in India and China combined. 
Recent trends have shown an increasing prevalence of diabetes in India (6, 46, 49). With 
the ongoing nutrition and lifestyle transition, there is higher probability of developing 
chronic diseases, as observed in Western countries.  Besides complications, T2DM also is 
associated with increased risk of colorectal cancer. With the recent trend, there is 






For all analyses, we will be using either the Mumbai Cohort Study (MCS) and 
Prostate Lung Colorectal or the Ovarian Cancer Screening Trial (PLCO) databases. AIM 
1: To determine the association between diabetes (T2DM) and all cancer incidence in an 
Indian database (MCS). We will also determine the association between diabetes and 
cancer subtypes. AIM 2: To determine the association between T2DM and colorectal 
cancer incidence in PLCO screening trial database. AIM 3 To examine the effect of 
duration of diabetes with colorectal cancer incidence and grades and stages of cancer. 
The details are mentioned below. 
Databases Used: 
Mumbai Cohort Study (MCS) 
MCS was conducted in Mumbai (formerly known as Bombay) in Maharashtra. 
Mumbai is a densely populated city that is divided into three parts: the main city, 
suburbs, and extended suburbs. The recruitment of participants was conducted from 
1991-1997 and follow-up was done from 1997-2003.  The study was restricted to the 
main city and recruited individuals over 35 years of age.  The voters list was used as the 
sampling frame and it provided information on age, sex, and address of individuals’ ≥ 18 
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years. The apartments serving the upper-middle class and upper-class housing complexes 
were gated communities and were not easily accessible to the interviewers, therefore they 
were excluded from the study (179).  Only people located in the study area were eligible 
to be recruited into the study. The interviewers conducted face-face interviews in the 
participant’s home using structured questionnaires. Handheld computers (electronic 
diaries) were utilized for this purpose. All the interviews were conducted in local 
languages (e.g., Marathi, Hindi) but the information was recorded in English. All the 
procedures regarding participant recruitment and ethical treatment of human subjects 
were approved by the Indian Council of Medical Research (ICMR) (179-181).  
Follow-up: A house-to-house follow-up was conducted on average of 5.5 years 
after the initial survey. A list of names and addresses of the participants was provided to 
the field investigators for re-interviewing the participant. If the participant was dead, 
information regarding the date and place of death was recorded with utmost care and 
accuracy. Participants who permanently migrated to another place were considered as 
withdrawn from the study and the date of migration was noted. Participants not available 
at the particular time and/or not available for re-interview after multiple visits, were 
censored at the date of revisit. Re-interviews were conducted during 1997-2003 (181).  
Prostate Lung Colorectal Ovarian Cancer Screening Trial (PLCO) 
The PLCO is a multicenter cancer screening trial (182). It was a randomized trial 
conducted with the main aim to determine if screening examinations can reduce the 
mortality of prostate, lung, colorectal, and ovarian cancer. Participants were enrolled and 
randomized in the years 1993-2001 from 10 different centers to different screening 
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procedures (for colorectal cancer – flexible sigmoidoscopy). .  Participants were aged 55 
years to 74 years. The exclusion criteria included history of prostate, lung, colorectal or 
ovarian cancer, ongoing cancer treatment for any cancer except basal-cell or squamous–
cell cancer.  People who had surgical removal of their entire prostate, entire colon or one 
lung were ineligible. People participating in other cancer screening or prevention trials 
also were excluded. Eligible participants were required to provide signed informed 
consent. All participants completed a baseline questionnaire, including information of the 
demographics, medical history, personal/family and past and history. Other information 
included screening data, dietary data, health status, collection of blood samples. An 
additional supplemental questionnaire was administered in 2006. This questionnaire 
consisted of similar information as collected in the baseline questionnaire with few 
additions (183).  
Aim 1: To determine the association between diabetes (T2DM) and all cancer 
incidence in an Indian database (MCS) 
Question 1: To determine the association between diabetes and cancer incidence 
adjusting for potential confounders like BMI and religion  
Question 2: To determine the association between diabetes and cancer subtypes  
Study Population: The manuscript will be based on the information collected from the 
MCS. As mentioned earlier, this study was conducted in Mumbai. 
Main Independent variable: Our main independent variable was T2DM. The 
information on diabetes mellitus was collected at baseline using the baseline survey. The 
question determining this information was an open-ended question ‘Do/ did you suffer 
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from any major disease in the past years (Y/N)___ If ‘Y’ then, disease name.  Although it 
is a self-reported questionnaire, the information was collected and entered by the 
interviewer.  
Dependent variable:  
Cancer incidence is defined as the occurrence of any new cases of cancer in the 
defined population during that specified time period. Cancers registered and first 
diagnosed between 1
st
 January and 31
st
 December of that particular year were considered 
incident cases for that year. Cancer cases also were selected if information was available 
only through death certificate.  
The Population Based Cancer Registry (PBCR) of Mumbai established in June 
1963 was the first such registry in India. Information was collected from cancer patients 
who were registered in 150 government hospitals/ institutions and private hospitals or 
nursing homes in Mumbai under the care of specialists.  Cases were excluded if they 
came under code ‘0’ = benign or ‘1’= uncertain if benign or malignant borderline 
malignancy or ‘2’=carcinoma in situ. Besides this, patients in whom cancer was ruled out 
or was not diagnosed were also removed. The World Health Organization coding system 
with the code number C00-97 as published in manual of the International Classification 
of Diseases, Injuries, and Cause of Death was used (184) .According to a paper published 
by International Agency for Research Cancer, the data collected by PBCR Mumbai meets 
the standards for completeness and reliability (185).  
The data from the Mumbai Cohort Study and PBCR were combined using the 
variables- Name, Sex, Age, Postal pincode, Religion, and Mother tongue. Information on 
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all the newly developed cancer cases ≥35 years developed from 1991-2003 was 
abstracted from PBCR.  
Covariates:  
We will check for all available covariates including age, sex, education, 
employment, marital status, body mass index, smoking status in the association. We will 
check for any interaction for BMI or religion. 
Inclusion/ Exclusion Criteria:  
Participants with missing information on diabetes and positive history of cancer at 
baseline will be excluded from the study.  
Statistical Analysis:  
Based on the aforementioned criteria, our analytic sample consists of 95,220 MCS 
participants. Descriptive statistics were calculated using chi-sq test for the categorical 
variables and t-test for the continuous variables. For our main analysis, we used Cox 
proportional hazards model examining cancer incidence among diabetics and non-
diabetics. Follow-up/Person years were calculated using the date of recruitment through 
31
st
 December 2003 until the date of re-interview, death, migration or cancer incidence. 
We checked for proportional hazards assumptions using both; graphical, and Schoenfeld 
residual method (186, 187). Based on this we conducted sequential modeling with first 
model representing the crude model; second model stratified by BMI (strata variable), the 




We adjusted for age, gender, native speech (including North Indian and South 
Indian languages), education (secondary/ college, primary/middle, uneducated), 
employment (employed, retired, unemployed, unknown), tobacco use (current user, past-
user, never-user), BMI (overweight/obese, normal, underweight) and religion (Hindu, 
Muslim, others). 
We grouped the diagnosed cancers into sub-categories ‘lip, oral-cavity and 
pharynx’ (C00-C14), ‘digestive organs cancers’ (C15-C26), ‘respiratory tract cancer’ 
(C30-C39), ‘breast, cervical, uterine, prostrate cancer’ (C50,C51-C55, C61), and others 
based on the ICD10 coding. For the initial analysis, we conducted a chi-sq test for each of 
these cancer subtypes (cancer subtype/ no cancer) by diabetes (yes/no) using the overall 
dataset. Following this, we conducted matching based on age, gender and person-time for 
each for these four cancer groups. The ratio used for matching was 1:4 for the ‘lip, oral-
cavity and pharynx’ (N=1230), ‘digestive organ cancer’ (N=1692) and ‘respiratory tract 
cancer’ (N=875) and 1:3 for ‘breast, cervical, uterine, prostrate cancer’ (N=1106). We 
conducted conditional logistic regression to determine the association between diabetes 
mellitus and cancer subtypes. 
Aim 2: To determine the association between T2DM and colorectal cancer incidence 
in PLCO screening trial database 
Question 1: To evaluate the association between diabetes and CRC incidence adjusting 
for potential confounders 




Study Population:  
We will use the Prostate Lung Colorectal Ovarian Cancer Screening Trial data for 
this project. 
Main Independent Variable:  
In this study, information on diabetes and 16 others diseases was collected using 
the baseline questionnaire and also via supplemental questionnaire that was one of the 
follow-up questionnaires. For this project we will use the baseline data. The question 
used to collect this information – ‘Has a doctor ever told you that you have any of the 
following conditions’.  It is a binary variable (yes/no). 
Main Dependent Variable:  
Colorectal cancer incidence is our main outcome. These data were collected using 
mailed annual study update (ASU) questionnaire that was mailed yearly around each 
anniversary of the participant’s randomization date. The ASU questionnaire consisted 
information on type and date of diagnosed cancer in the past year. Non-respondents were 
contacted again by the study staff via mail and telephone. Information on cancer 
incidence was verified using medical records.  
Covariates:  
The baseline questionnaire consisted of information on socio-demographic, 
anthropometric, and personal medical history. Dietary data were collected twice 
throughout the course of the study. At baseline the data was collected only in the 
intervention arm and it was administered again from 1998-2001 in both the intervention 
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and control arms. We used the dietary inflammatory index (DII
TM
), a tool used for 
calculating the inflammatory level of food. DII was determined using the diet history 
questionnaire (DHQ) administered to both the screening arms Around 118,804 
participants have information on diet. The DII is based on 45 food parameters (188). In 
our study it was calculated based on the 37 parameters available in the DHQ.  
Inclusion/ Exclusion Criteria:  
Participants with missing data on diabetes status at baseline will be excluded.  
Statistical Analysis:  
Figure1 provides the information used for creating the final analytic dataset. 
Baseline characteristics were estimated by diabetes status. Person-time (in days) were 
calculated from the baseline date to the date of cancer incidence or the latest completion 
date of ASU, death, or 13 year of cut off, whichever occurred first. We adjusted for sex, 
age (<60 years, 60-70 years, >70 years), BMI (<25, 25–29.9, and 30 kg/m
2
 and 
unknown), education (≥college, post high school/some college, <high school), family 
history of cancer (yes, no, missing), aspirin intake (>2/day,1/day, 1-4/week, <4/month 
and none), cigarette smoking (current, former, non smoker), DII in tertiles (<-2.74, <-
0.39, >=-0.39). For all our analytical models using Cox proportional hazards model, we 
checked for the proportional hazards (PH) assumption.  Once satisfied, we fit these 
models estimate hazards ratios and 95% confidence intervals controlling for important 
covariates.  
For our initial analysis, we did not include the diet information as a covariate. For 
the overall sample size (N= 145,642) BMI was included as a strata variable as it did not 
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satisfy the PH assumption. For our further analysis, participants with a person-time of 0 
were deleted from the study.  Also, only participants with a confirmed cancer status 
(yes/no) were included in the study.  
Separate analyses were conducted by stratifying the models by the intervention 
arm and BMI to check if screening and BMI modified the association between diabetes 
and CRC. BMI was re-categorized into (normal/underweight, overweight and obese) for 
stratified analysis. While checking for BMI, we conducted the analysis, initially with the 
overall data (N=145,642) and again in the dataset with dietary data (N=114,017), as 
shown in Figure1. Physical activity was collected using the baseline dietary and the 
supplemental questionnaire (SQX). However the baseline information was collected only 
in the intervention arm. We also performed sensitivity analysis, removing people with 
missing physical activity data (as per the SQX administered in 2006). Sensitivity analysis 
was also conducted restricting to participants with person-time of more than1 year and 2 
years with sample sizes of (N=113,689) and (N=113480) respectively. 
Aim 3: To examine the effect of duration of diabetes with colorectal cancer 
incidence and grades and stages of cancer 
Question 1: To assess the association between duration of diabetes associated with 
colorectal cancer incidence adjusting for the potential confounders 
Question 2: To check if duration of diabetes is related to cancer aggressiveness (cancer 
stage and grade) 
Study Population: We will use the Prostate Lung Colorectal Ovarian Cancer Screening 
Trial data for this project. 
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Main Independent Variable: Duration of diabetes 
The baseline (BQX) and supplemental (SQX) questionnaires were used to 
determine this variable. The BQX and SQX were administered at baseline and years 
2006-2008 respectively. BQX included the question “Did the participant ever have 
diabetes?” and the SQX used the question “Were you ever diagnosed with diabetes?”  
The SQX also included information on the age at diagnosis of diabetes with 4 categories 
(<50 years, 50-59years, 60-69years and >70years).  
Participants with missing information on diabetes in both BQX and SQX were 
deleted. The overall sample with a valid SQX consists of 103,758 participants. For the 
estimation of duration of diabetes variable, we included participants who mentioned yes 
for diabetes in the SQX. Among the participants who mentioned yes for diabetes in the 
SQX (N=13,675), 12,927 participants answered the question regarding the age at 
diagnosis. For the final calculation, we subtracted the mean of the range for the 50-59 
years (i.e., 54.5 years) and 60-69 years (i.e., 64.5 years) from the age of the participant 
when the SQX was answered. For the last category (>70 years), we will use the mean of 
70 years and the highest age of the participant during the SQX i.e. (87 years) (i.e. 78.5) 
and subtract it from the age of participant. Using this method, we get negative values for 
some of the participants for the calculated variable. As duration of diabetes cannot be less 
than 0, we convert these numbers to 1 (minimum possible value).  Figure1 gives the 
distribution of the participants used for determining the diabetes status. Based on this 
information the variable diabetes duration was categorized into ‘no diabetes’, 
‘<=10years’, and ‘>10years’.  
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Main Dependent Variable: Colorectal Cancer (CRC) incidence, stage, and grade  
CRC incidence data were collected using Annual Study Update Questionnaire 
(ASU) administered annually. The incidence, stage and grade of CRC were confirmed 
using medical records. For the final analysis, participants with confirmed status of CRC 
(yes/no) were included. CRC grades I and II were combined and considered low grade 
while grade III and IV were grouped together as high grade. For determining CRC stage, 
we used information combining the clinical and pathologic stage of CRC and similar to 
grade, stage I and II were combined and stage III and IV were combined. Accordingly, 
the sample size was 1032 and 1073 for CRC grade and CRC stage as outcomes 
respectively.  
Statistical Analysis:  
Descriptive statistics (chi-sq for categorical and t-test for continuous variables) 
were calculated for participants by their diabetes duration. For CRC incidence, the 
following exclusion criteria were used. Participants with missing data on the variable 
‘age at diagnosis’ in the SQX, missing information on education, an invalid SQX were 
deleted. Person-years were calculated from the day of entry in the trial to CRC diagnosis, 
or last day of remaining free from cancer and/or death of the participant. Cox 
proportional hazard model was used to estimate hazards ratio and 95% Confidence 
interval (CI) of CRC incidence by diabetes duration. 
We adjusted for age (when SQX was answered), race (non-Hispanic white, non-
Hispanic black and others), screening arm (intervention, control group), BMI (<25, 25–
29.9, and 30 kg/m
2 
and unknown), gender, employment status (employed, unemployed, 
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retired and others), education (graduate and more, high school/some college, and less 
than high school), aspirin intake in past 12 months (≤1/week, ≥2/week, none, unknown), 
smoking status (current smoker, past smoker, non-smoker and unknown), family history 
of colorectal cancer (yes, no, missing) and DII (dietary inflammatory index) score, 
physical activity (active –yes, no, missing).DII is a tool measuring the inflammatory level 
of food. It is calculated using up to 45 food parameters, and based on availability of these 
parameters.  In our study it was based on 37 parameters, which is at the upper end of 
what is available from structured questionnaires such as food frequency questionnaires 
(FFQ). The details regarding DII have been provided elsewhere (188).  We checked the 
proportional hazards (PH)-assumptions for diabetes duration and other covariates. As 
BMI did not satisfy the PH-assumption, we conducted stratified analysis. Figure 2 
provides the final sample used for analysis (N= 83,904).  
For CRC stage and grade as the outcomes, the data were restricted to participants 
with information on stage and grade, respectively. Further, the people with missing data 
on aspirin intake and cigarette smoking were deleted. Logistic regression was used to 
estimate odds ratio (OR) and 95% confidence interval (CI) for CRC stage and grade by 
duration of diabetes. 
Sensitivity analysis was conducted, deleting participants with diagnosis of CRC 




Overall Strengths and Limitations: 
Strengths: Through our first aim we will be determining the association in India using a 
longitudinal database, where the question has not yet been studied. The study design will 
also help in determining the temporal sequence of the association.  
In our Aim 2 and Aim 3, we are using a US national database (PLCO trial). In the 
PLCO data, we have information on screening for colorectal cancer. Most of the previous 
studies have diagnostic bias as one of the main limitations. Through this study, we will 
try to address this problem. We will also be looking at the impact of duration of diabetes 
with cancer incidence and aggressiveness. We will include DII – a new concept 
especially in this association. In the existing literature it was observed that only few 
dietary ingredients were included in the models, while in our study, the dietary 
component included, is based on the total dietary intake.  
Limitations: In both the study databases, diabetes is self-reported. In the MCS, 
although the data for self-reported, it was entered by the interviewer and in the PLCO 
database, one of the follow-up questionnaires includes data on diabetes and its duration. 
We will validate the data using these two questionnaires. For our MCS study, we do not 
have information on a lot of covariates like diet and physical activity
Shraddha Vyas, Angela Liese, Jiajia Zhang, Nitin Shivappa, Prakash Gupta, James R Hebert. To 




ASSOCIATION BETWEEN DIABETES MELLITUS AND CANCER AND 
CANCER SUBTYPES IN INDIAN POPULATION 
Abstract 
Background: There is growing evidence of association between diabetes and cancer. No 
studies have been conducted in India evaluating this association. With the current 
epidemiologic, nutritional and economic transition in India, it becomes extremely 
important to examine this association in an Indian population. 
Method: We used Mumbai Cohort Study- a longitudinal study for this purpose. Diabetes 
information was collected at baseline and cancer information was received via follow-up 
questionnaire and confirmed using cancer registry. We also evaluated the association 
between diabetes and cancer subtypes after creating matched datasets for each cancer 
subtype. We used Cox Proportional model for cancer incidence and conditional logistic 
regression for cancer subtypes.  
Results: We did not observe any significant associations between diabetes and all cancer 
incidence and cancer subgroups. However the association was in the expected direction. 
The hazard of all cancer incidence was 1.06 (95%CI=0.75, 1.62) among persons with 
diabetes as compared to people without diabetes.. Among cancer subtypes, there was an 
increased risk of ‘lip/oral/pharyngeal cancer’ (OR=1.83; 95%CI=0.86, 3.86) and
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 ‘respiratory tract cancer’ among people with diabetes (OR=1.28; 95%CI=0.53,3.13) 
respectively.  Inverse direction was observed for ‘digestive organ cancer and 
‘breast/prostate/uterine/cervical cancer’ among people with diabetes compared to people 
without diabetes (OR=0.59; 95%CI=0.27, 1.32) and (OR=0.66; 95%CI=0.24, 1.84) 
respectively, but none of these associations reached statistical significance. 
Conclusion: Our findings appear to show a higher hazards of all cancer incidence, 
lip/oral/pharyngeal and respiratory tract cancer among people with diabetes compared to 
people without diabetes. They direction of the association is consistent with previous 
study results. However the association is not significant. Future studies needed to explore 




Apart from the diabetic complications like diabetic foot, diabetic ketoacidosis, 
diabetes has also been linked with other chronic diseases like hypertension, other 
cardiovascular diseases (189-192). Several studies have shown an association between 
diabetes mellitus and cancer. Literature suggests an increased risk of colorectal cancer 
(28-40, 42, 61, 76, 124), breast cancer (31, 193-195), liver cancer (196, 197), and 
pancreatic cancer (198-200) among people with diabetes. On the other hand people with 
diabetes are associated with a lower risk of prostate cancer (59, 201, 202). Besides sites-
specific mechanisms for certain cancers like pancreatic and liver cancer, 
hyperinsulinemia, chronic inflammation and hyperglycemia are the suggested pathways 
in this association  (28, 31-33, 43, 58, 95, 193, 194, 196, 198).  
To date, most of these studies determining the association between diabetes 
mellitus and cancer are in the Western nations (29, 30, 33, 37, 39, 40, 57, 61-64, 66, 193, 
194, 202-207). None of these studies are conducted in India, which is currently 
experiencing dramatic demographic, economic, epidemiologic and nutrition transitions 
(5, 8, 9, 13-15, 122, 123) and diabetes is developing the status of an epidemic. India is 
also a diverse country in terms of religion and culture and people in different religions 
have a different dietary and lifestyle habit that have also linked with these diseases. 
Globally the Indian population is more prone to metabolic syndrome (128-130). Indians 
are also at a higher risk of diabetes mellitus, CVD, dyslipidemia, even at a lower or 
normal BMI (208-210).  Similar results are seen among Asian Indians worldwide. 
Although, compared to Western countries, the cancer rates are lower in India; they are 
still on increasing trend (211-214). Additionally, with the current ominous changes in 
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above-mentioned lifestyle factors, it is likely that cancer rates will increase. Thus, it 
becomes important to study this association in India. In our study, we will assess the 
association between diabetes mellitus and cancer incidence and cancer sub-types in an 
Indian population.  
Methods 
Study Design 
Baseline: The Mumbai Cohort Study (MCS) was conducted in Mumbai 
(previously known as Bombay) in Maharashtra. The participants were recruited from 
1991-1997 and the follow-up was conducted from 1997-2003.  The study was restricted 
to the main city and recruited individuals over 35 years of age.  The voters’ list was used 
as the sampling frame and it provided information on age, sex, and address of individuals 
who are ≥ 18 years. The apartments serving the upper-middle class and upper-class 
housing complexes were essentially gated communities and were not easily accessible to 
the interviewers, therefore they were excluded from the study (179).  Footpath dwellers, 
who did not have a permanent residence also were excluded because they are not 
generally included in the electoral rolls; hence they would be very difficult to follow-up 
(180, 184, 215-218).  Of all of the major cancer cohorts in the world, the MCS is the 
more diverse in terms of income and socioeconomic status more generally. Only people 
located in the study area were eligible to be recruited into the study. Face-to-face 
interviews were conducted using structured questionnaires in handheld computers 
(electronic diaries) by interviewers in the participant’s home. All of the interviews were 
conducted in local languages (e.g., Marathi, Hindi) but the information was recorded in 
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English. All the procedures regarding participant recruitment and ethical treatment of 
human subjects were approved by the Indian Council of Medical Research (ICMR) (179-
181).  
Follow-up: A list of names and addresses of the participants were provided to the 
field investigators for re-interviewing the participants. A house-to-house follow-up 
interview was conducted on an average of 5.5 years after the initial survey. If the 
participant had died, information regarding the date and place of death was accurately 
recorded. For the participants who permanently migrated to another place their date of 
migration was noted. (181).  
Main Independent variable: 
Our main independent variable was T2DM. The information on diabetes mellitus 
was collected at baseline using the baseline survey. The question determining this 
information was an open-ended question ‘Do/ did you suffer from any major disease in 
the past years (Y/N)___ If ‘Y’ then, disease name.’  Although it is a self-reported 
questionnaire, the information was collected and entered by the interviewer.  
Dependent variable: 
Cancer incidence was defined as the occurrence of any new cases of cancer in the 
defined population during that specified time period. Cancers registered and first 
diagnosed between the 1
st
 January and the 31
st
 December of that particular year were 
considered incident cases for that year. Cancer cases also were selected if information 
was available only through death certificate. The cancer information (status and date of 
diagnosis) was confirmed using the population-based cancer registry (PBCR). The PBCR 
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in Mumbai was the first registry to be established in India, in June 1963. Information was 
collected from cancer patients who were registered in 150 government hospitals/ 
institutions and private hospitals or nursing homes in Mumbai under the care of 
specialists.  Cases were excluded if they came under code ‘0’ = benign or ‘1’= uncertain 
if benign or malignant borderline malignancy or ‘2’=carcinoma in situ. The World 
Health Organization coding system with the code number C00-97 as published in manual 
of the International Classification of Diseases, Injuries, and Cause of Death was used 
(184). According to a paper published by the International Agency for Research on 
Cancer, the data collected by PBCR Mumbai met the standards for completeness and 
reliability (185). The data from the Mumbai Cohort Study and PBCR were combined 
using these variables: Name, Sex, Age, Postal pin code, Religion, and Mother tongue. 
Information on all the newly diagnosed cancer cases ≥35 years developed from 1991-
2003 was abstracted from PBCR.  
Inclusion/ Exclusion Criteria: The overall sample size at baseline is 148,173. 
Participants with missing information on diabetes mellitus and a person-time of ≤0 were 
excluded from the study. Participants with a past history of cancer also were deleted. For 
further analysis, participants with missing information on employment status, mother-
tongue and with a follow-up status of ‘unknown’ and ‘other’ were removed from our 





Statistical Analysis:  
Descriptive statistics were calculated using chi-sq test for the categorical variables 
and t-test for the continuous variables. For our main analysis, we used Cox proportional 
hazards model examining cancer incidence among people with diabetes and people 
without diabetes. Follow-up/Person years were calculated using the date of recruitment 
through 31
st
 December 2003 until the date of re-interview, death, migration or cancer 
incidence. We checked for proportional hazards assumptions using both; graphical, and 
Schoenfeld residual method (186, 187). Based on this we conducted sequential modeling 
with first model representing the crude model; second model stratified by BMI (strata 
variable), the third model including BMI in the final model to check if BMI also has an 
impact on cancer incidence. 
We adjusted for age, gender, native speech (including North Indian and South 
Indian languages), education (secondary/ college, primary/middle, uneducated), 
employment (employed, retired, unemployed, unknown), tobacco use (current user, past-
user, never-user), BMI (overweight/obese, normal, underweight) and religion (Hindu, 
Muslim, others). Additionally, we also considered native speech and religion. These 
factors could also act as potential confounders considering the fact that diet and other 
factors change significantly among these religions and language.   
We grouped the diagnosed cancers into sub-categories ‘lip, oral-cavity and 
pharynx’ (C00-C14), ‘digestive organs cancers’ (C15-C26), ‘respiratory tract cancer’ 
(C30-C39), ‘breast, cervical, uterine, prostate cancer’ (C50,C51-C55, C61), and others 
based on the ICD10 coding. For the initial analysis, we conducted a chi-sq test for each of 
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these cancer subtypes (cancer subtype/ no cancer) by diabetes (yes/no) using the overall 
dataset. Following this, we conducted matching based on age, gender and person-time for 
each for these four cancer groups. The ratio used for matching was 1:4 for the ‘lip, oral-
cavity and pharynx’ (N=1230), ‘digestive organ cancer’ (N=1692) and ‘respiratory tract 
cancer’ (N=875) and 1:3 for ‘breast, cervical, uterine, prostate cancer’ (N=1106). We 
conducted conditional logistic regression to determine the association between diabetes 
mellitus and cancer subtypes.  
Results: 
Descriptive characteristics of the participants, in relation to their diabetes mellitus 
status are summarized in Table 4.1. People with diabetes were comparatively older with a 
mean age of 59.2 years. Across the two groups, males (79.8% vs 66.2%), and participants 
of Muslim and other religion  (17.3% vs. 13.9% & 8.2% vs 6.2% respectively) were more 
common among people with diabetes compared to those without diabetes.  Participants 
speaking languages of Dravidian origin (South Indian languages including Tamil, 
Kannada, Telugu and Malayalam) were more common among people with diabetes than 
people without diabetes (16.2% vs. 9.7%). Around 60% of participants in both the groups 
had at least primary/ middle level of education. People with diabetes had a higher percent 
of participants with secondary school or college education (23.9% vs. 12.5%), and were 
more obese/overweight (37.5% vs. 23.4%). 
Similar to the crude model, in our final adjusted model the hazards of cancer 
incidence appeared to be higher among people with diabetes compared to those without 
diabetes although it did not reach the statistical significance (crude model- HR=1.11; 
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95%CI=0.78, 1.58, adjusted model-HR=1.06; 95%CI=0.75, 1.52) (Table 4.2). Among the 
other covariates, gender, religion, tobacco use had a significant effect.   
Table 5.3 represents the difference in the proportion of cancer subgroups as 
compared to people without cancer by their diabetes status. The ‘lip/oral cavity/pharynx’ 
cancer group was significantly different between people with diabetes as compared 
people without diabetes (p-value=0.0192). None of the other cancer subgroups showed 
any significant difference. Table 5.4 provides the conditional odds ratio for the different 
cancer subgroups. Both, the crude and adjusted model did not produce significant results. 
We adjusted for age, religion, native speech, education, BMI and overall tobacco intake. 
In the adjusted model, people with diabetes appeared to show a higher odds of 
lips/oral/pharynx cancer (OR=1.83; 95%CI=0.86, 3.86) and respiratory tract cancer 
(OR=1.28; 95%CI=0.53, 3.13) as compared to those without diabetes. Opposite results 
were observed for digestive and hormone related cancers i.e. the odds of cancer were 
lower among people with diabetes compared people without diabetes (OR=0.63; 
95%CI=0.28, 1.44) (OR=0.66, 95%CI=0.24, 1.84) respectively.  
Discussion 
In our study we examined the association between diabetes and the risk of 
developing cancer using a longitudinal study conducted in India. The results were not 
significant, however the estimates were in the expected direction i.e. the risk of all cancer 
incidence was higher among people with diabetes.  
Existing literature assessing the relation between diabetes and all cancer incidence 
have inconsistent results. Zhang et al. in their retrospective cohort study in China, 
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suggested an increased incidence ratio of overall cancer risk in both men and women 
among people with diabetes (SIR=1.33; 95%CI=1.14, 1.52 and SIR=1.74; 95%CI= 1.48, 
2.00 respectively) (204). Another study from Denmark demonstrated similar results and 
found a 10% increased risk of cancer among people with diabetes. As opposed to the 
above results, one of the studies conducted in Scotland, suggested no significant 
association between diabetes and overall cancer incidence (62).    
We regrouped cancer in different subtypes based on ICD10 categories. Our results 
showed increased odds of ‘lip/oral cavity and pharynx’, and ‘respiratory tract’ cancer 
among people with diabetes compared to those without diabetes, however the results 
were not significant. A retrospective study in Hungary showed that participants with oral 
cancer had 14.6% people with diabetes, which was higher than people without oral 
cancer (219).  Wideroff et al. in his study demonstrated a higher risk of oral/pharyngeal 
and esophageal cancer in people with diabetes under the age of 50 years (220).  With 
regards to lung cancer, most of the previous studies did not show significant association 
with diabetes (204, 220). For digestive tract cancer, we observed an inverse relation i.e. 
people with diabetes had a decreased odds of digestive tract cancer compared to those 
without diabetes contrary to the results found by Wideroff et al. that showed an elevated 
risk of digestive tract cancer (including esophageal, stomach, small intestine, colon, 
rectum, liver, biliary tract and pancreatic cancer) among people with diabetes (220). In 
this study the digestive tract cancers included esophagus, stomach, colon and liver & 
intrahepatic bile duct cancer while the people without diabetes had a number of other 
cancers included in this group. Similar to digestive tract cancer, we found an inverse 
direction for hormone-related cancers. The probable reason could be the higher number 
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(four of five) of prostate cancer cases among people with diabetes and only one 
participant with breast cancer. Although the results were insignificant, the direction is 
consistent with most of the previous studies showing an inverse association in relation to 
prostate cancer (59, 203, 207). Two meta-analysis also showed similar results (201, 202).   
Hyperinsulinemia is suggested to be one of the major connecting links in the 
association between diabetes and cancer suggesting an increased level of insulin and 
insulin-like growth factor. Both, insulin and IGF-I are involved in cell growth initiation 
and progression by proliferation and IGF-I also act as an inhibitor of apoptosis. 
Additionally obesity is considered to be a predisposing factor for both diabetes and 
cancer. Especially abdominal adiposity (visceral obesity) is more strongly associated with 
these chronic diseases (221, 222). Asian population is more prone to abdominal obesity 
and other chronic diseases even at a lower BMI. Furthermore, chronic inflammation is 
associated with insulin-resistance thereby considered to be one of the links between 
diabetes, obesity and cancer. All these factors, individually or in connection with each 
other lead to an increased risk of cancer.   
One of the major limitations of our study is the study population which is not 
representative of the entire population as the upper –middle-class and upper class housing 
complex could not be included during the recruitment due to security issues. We had a lot 
of missing data for our main independent variable i.e. diabetes. In our study, the results 
were directed towards null, which could be probably due to the data not missing at 
random. We could not adjust for potential confounders like diet and physical activity due 
to lack of information. Despite the limitations this study has several strengths. MCS is a 
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longitudinal study conducted with a very diverse population and has a large sample size. 
Although the diabetes status was self-report it was hand entered by the interviewer.  
This is the first study evaluating the association between diabetes and cancer in an 
Indian population. Studies are required determining this association in further details 
especially in an Indian population where the diabetes rates are increasing at an alarming 
rate (223). In these studies we need to consider all the factors that can act as potential 
confounders as a lot of studies lack this information. Furthermore, differences also exist 
in the socio-demographic characteristics (like education, tobacco use) among the Indian 
population as compared to the other western population. Assessment of these risk factors 
could help in better understanding of the association. Additionally, better registries are 




Table 4.1: Descriptive Statistics for the overall population by diabetes mellitus status, 
Mumbai Cohort Study, Mumbai Maharashtra, 1991-2003. 
 
    Diabetes mellitus   
Variables  Yes (N=2143) No (N=93077) p-value 
    Mean(±std)   
Age   59.2 (±9.8 ) 51.6 (±11.1) <.0001 
    % (N) 
 Gender                             Male 79.8 (1,710) 66.2 (61,606) 
<.0001 
  Female 20.2 (433) 33.8 (31,471) 
Religion                              Hindu 74.5 (1596) 79.9 (74,354) 
<.0001 
 
Muslim 17.3 (370) 13.9 (12,910) 
  Others 8.2 (177) 6.2 (5,813) 
Primary                           Aryan  83.8 (1,796) 90.3 (84,056) 
<.0001 




23.9 (511) 12.5 (11,616) 
<.0001 
 
Primary / middle 
school 
59.6 (1,278) 63.1 (58,782) 
  Uneducated  16.5 (354) 24.4 (22,679) 
Employment  Employed 38.3 (822) 46.8 (43,593) 
<.0001  
Unemployed 15.5 (332) 30.7 (28,584) 
 
Retired 41.5 (889) 19.7 (18,332) 
  Unknown 4.7 (100) 2.8 (2,568) 
Tobacco 
Use     
Current user 51.7 (11.7) 58.1 (54,072) 
<.0001 
 
Past user 12.1 (259) 4.9 (4,518) 





Obese/ overweight 37.5 (804) 23.4 (21,774) 
<.0001 
 
Underweight 5.5 (117) 18.3 (17,073) 






Table 4.2: Unadjusted model - HR (95%CI) for all cancer incidence by diabetes mellitus, 
Mumbai Cohort Study, Mumbai Maharashtra, 1991-2003  
 
  All cancer incidence   
Reported Regression Estimate HR (95% CI) P-value 
Unadjusted     
Diabetes (yes/no) 1.11 (0.78,1.58) 0.55 
Adjusted model with BMI as a strata variable     





Table 4.3: Distribution of cancer subtypes across four categories of cancer, Mumbai 
Cohort Study, Mumbai Maharashtra, 1991-2003. 
 
Table of Cancer type by diabetes  
CANCERTYPE 
Diabetes % (N)   
yes  No p-value 
Lip/oralcavity/pharynx Cancer 0.51% (11) 0.25% (235) 0.0192 
Digestive organ Cancer 0.33% (7) 0.36% (332) 0.8179 
Respiratory tract Cancer 0.33% (7) 0.18% (168) 0.1193 
Breast/Cervical/uterus/prostate Cancer 0.23% (5) 0.30% (281) 0.5672 








Table 4.4: Conditional OR (95%CI) for cancer subtypes in relation to diabetes mellitus, Mumbai Cohort Study, Mumbai 
Maharashtra, 1991-2003 
 













HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Unadjusted     
Diabetes (yes/no) 1.39 (0.69, 2.81) 0.59 (0.27,1.32) 1.12 (0.48, 2.59) 0.75 (0.28, 2.00) 
Adjusted model      
Diabetes (yes/no) 1.83 (0.86,3.86) 0.63 (0.28,1.44) 1.28 (0.53,3.13) 0.66 (0.24,1.84) 
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ASSOCIATION BETWEEN DIABETES AND COLORECTAL CANCER 
INCIDENCE- A LONGITUDINAL STUDY IN THE US POPULATION 
Abstract 
Background: Research has shown that diabetes is associated with an increased risk of 
colorectal cancer. However most of these studies suggest detection bias to be one of the 
probable reasons for this association. Additionally, the common risk factors shared by 
both these conditions are considered to one of the reasons in the association.  
Objective: In this study, we examine the association between diabetes and CRC, 
accounting for important potential confounders and also check for detection bias.  
Methods: We used the Prostate Lung Colorectal Ovarian (PLCO) Cancer screening trial. 
The diabetes information was self-report data and collected at baseline. The cancer 
information was collected using annual survey questionnaire (ASU) administered every 
year and confirmed using medical records. For our final analysis we use cox proportional 
hazards model. To evaluate the notion of detection bias, we conducted stratified analysis.  
Results: We observed a 33% higher risk of CRC among people with diabetes as 
compared to people without diabetes. After stratifying the results by screening arm, we 




among the control arm (HR=1.22, 95%CI=0.94, 1.58). After stratifying by BMI, the risk 
was still high among people with diabetes in all the groups. 
Conclusion: Our findings showed an association between diabetes and increased risk of 
colorectal cancer. Detection might not be the reason for this association. Further studies 





Type 2 Diabetes Mellitus (T2DM) and cancer are both among the top 10 leading 
causes of mortality worldwide (1-3). Apart from the established diabetic complications, 
existing literature suggests an increasing risk of cancer among people with diabetes. 
Evidence shows that people with diabetes have an increased risk of colorectal cancer 
(CRC) (28-40, 42, 59, 61, 76, 124). Hyperinsulinemia is suggested to one of the 
mechanisms in this association. Both insulin and IGF-I act as a growth stimulator and 
inhibitor of apoptosis, thereby promoting carcinogenesis within the colonic epithelium 
(31, 32, 43, 224).  
In addition to this, both these diseases have a lot of common risk factors like lack 
of physical activity, obesity and unhealthy dietary habits. As seen from literature, diet 
high in total energy, fat, red meat, and carbohydrates and low in fruits and vegetables 
elevate the risk of CRC through inflammatory pathways (44, 142-150). Diets high in total 
calories and saturated fat and low levels of dietary fiber also lead to insulin resistance, 
which in turn is associated with both T2DM and CRC (82). Inflammatory pathways are 
also suggested as one of the mechanisms underlying the association between T2DM and 
CRC risk (34-36, 43, 224). Therefore diets with an inflammatory potential can also play a 
role in this association.  
Although there is a lot of existing literature, most of the previous studies mention 
detection bias as one the probable reasons leading to this association. People with 
diabetes are more likely to visit their physicians and thereby have a higher probability of 
being diagnosed by other diseases (29-35, 37, 39, 76, 205). Apart from detection bias 




risk factors for both these diseases. Majority of the studies assessing the role of diet in the 
association have just focused on specific dietary components. Diet, as a whole can 
altogether have a different effect on these diseases..  
There is a global increase in the T2DM rates and even though the rates of CRC 
are decreasing, the incidence and prevalence of CRC is still high among the US 
population. It still remains one of the top 3 causes of cancer deaths in both men and 
women (20). Diabetes and cancer affect the health and economy at both; individual and 
national level.  
Considering the facts and gaps in literature, in our study we aim to address those 
questions. We will evaluate if there is any association between T2DM and CRC 
incidence accounting for the possibility of detection bias. We will also check if BMI and 
dietary inflammatory index (DII) modify this association. DII is a unique tool measuring 
the overall inflammatory potential of a diet that will help in understanding the role of diet 
on this association 
Materials and methods 
Study population 
This study is conducted using data from the Prostate Lung Colorectal Ovarian 
(PLCO) Cancer Screening Trial. The PLCO is a multicenter screening trial conducted 
with the aim of understanding the importance of screening examinations on reduction of 
mortality rates of cancers of the prostate, lung, colorectal and ovarian. Participants were 
enrolled from 10 different centers and randomized in the years 1993-2001. Around 




77,000 of these individuals were randomized to both study arms. A series of 
questionnaires were administered throughout the course of the study. The demographic, 
anthropometric and medical history information was collected from baseline and 
supplemental questionnaires. Diet information was collected twice during the course of 
the study- at baseline from the intervention arm and from 1998 to 2001 from both the 
screening arms that include the intervention and the control arm, using a food frequency 
questionnaire.  
For our study, we used the following exclusion criteria; a) participants with 
baseline colorectal cancer, b) People with no information on diabetes. We excluded 
participants with missing information on the following covariates; employment, 
education, family history of colorectal cancer, aspirin intake and cigarette smoking. The 
final sample size consisted of 146,918 participants. Other details regarding the study 
design and methods have been summarized elsewhere (183).  
Main Dependent Variable: Colorectal Cancer Incidence  
The cancer incidence data were collected using the annual study update 
questionnaire (ASU), administered every year to each participant on the date of 
randomization. The ASU collected information on the type and date of diagnosed cancer 
in the past year. This information was confirmed through medical records. Non-





Independent variables  
The baseline questionnaire included information on diabetes and other 19 medical 
conditions. Although the diabetes data were self reported, studies have shown these 
results to be accurate, especially for diseases like diabetes and hypertension (225-229).  
Covariates: 
 The baseline questionnaire consisted of information on socio-demographic, 
anthropometric, and personal medical history. Dietary data were collected twice 
throughout the course of the study using food frequency questionnaire. At baseline the 
data was collected only in the intervention arm and it was administered again from 1998-
2001 in both the intervention and control arms. We used the dietary inflammatory index 
(DII
TM
), a tool used for calculating the inflammatory potential of diet. DII was 
determined using the diet history questionnaire (DHQ) administered to both the screening 
arms. Around 118,804 participants have information on diet. The DII is based on 45 food 
parameters (188). In our study it was calculated based on the 37 parameters available in 
the DHQ. A higher DII score indicates a pro-inflammatory diet.  
Statistical Analysis:  
Based on the inclusion/ exclusion criteria, we determined the final analytic dataset 
as provided in Figure1. Baseline characteristics were estimated by diabetes status. For the 
categorical variables, we used chi-sq test and t-test for the continuous variables. Person-
time (in days) was calculated from the baseline date to the date of cancer incidence or the 
latest completion date of ASU, death, or 13 year of cut off, whichever occurred first. We 






 and unknown), education (≥college, post high school/some college, <high 
school), family history of cancer (yes, no, missing), aspirin intake (>2/day,1/day, 1-
4/week, <4/month and none), cigarette smoking (current, former, non-smoker), DII in 
tertiles (<-2.74, <-0.39, >=-0.39). For all our analytical models using Cox proportional 
hazards model, we checked for the proportional hazards (PH) assumption. Once the ph-
assumption was satisfied, we fit these models and estimated the hazards ratios and 95% 
confidence intervals, controlling for important covariates.  
For our initial analysis, we did not include the diet information as a covariate. For 
the overall sample size (N= 145,642) BMI was included as a strata variable as it did not 
satisfy the PH assumption. For our further analysis, participants with a person-time of 0 
were deleted from the study.  Also, only participants with a confirmed cancer status 
(yes/no) were included in the study.  
Separate analyses were conducted by stratifying the models by the intervention 
arm and BMI to check if screening and BMI modified the association between diabetes 
and CRC. BMI was re-categorized into three strata (normal/underweight, overweight and 
obese). For analysis, with BMI, we used two sample sizes i.e. initially with the overall 
data (N=145,642) and again with dataset including the dietary data (N=114,017), as 
shown in Figure1. Physical activity was collected using the baseline dietary and the 
supplemental questionnaire (SQX). However the baseline information was collected only 
in the intervention arm. We also performed sensitivity analysis, removing people with 
missing physical activity data (as per the SQX administered in 2006). A sensitivity 
analysis was conducted by restricting to participants with person-time of more than1 year 





The distribution of socio-demographic, lifestyle characteristics of participants by 
their diabetes status in the PLCO study is provided in Table 5.1 (N=114,017). The sample 
size was significantly different across the two groups. Compared to people without 
diabetes, people with diabetes had a higher proportion of male (57% vs. 47.5%), Non-
Hispanic Blacks (8.7% vs. 3.2%) and other group (9.6% vs. 5.5%) participants, tended to 
be older age group (73.5% vs 65.9% in >60years group).  Also, people with diabetes had 
a higher percent of obese (44.5% vs 21.8%) compared to those without diabetes. 
However, people without diabetes had a relatively higher proportion of overweight (i.e., 
25≤BMI<30kg/m
2
) participants (42.4% vs. 37.7%). In both the groups fewer than 10% of 
participants were current smokers (8% people with diabetes vs. 9.6% people without 
diabetes). However the sample was almost similarly distributed for the intervention and 
control arm across the two groups. Around 87% of participants had no family history of 
colorectal cancer in both the groups. More than 50% of participants had some intake of 
aspirin in the people with diabetes as compared to people without diabetes, where the 
aspirin intake was less than 50%.  
During the follow-up of 13 years, 1622 cases of CRC were detected. Table 5.2 
provides the results for the crude model (Table 5.2), the adjusted model (Table 5.3) in the 
overall sample size (figure1 (a)) and the final sample including the diet data (figure1 (b)) 
(Table 5.4). In the crude model, the hazards of CRC incidence was significantly higher 
among people with diabetes (HR-1.56; 95%CI, 1.33- 1.84) compared to people without 
diabetes. After adjusting for the potential confounders, the risk was higher among people 




of 1.40 (95%CI, 1.22-1.61) in the overall model and hazards ratio of 1.32 (95%CI, 1.12-
1.57) in the final analytical sample size.  
When stratified by the screening arm, the hazard ratios were higher among people 
with diabetes in both the intervention and control group. It was significant in the control 
group (HR-1.42; 95%CI, 1.14-1.77), unlike in the intervention group (HR-1.22; 95%CI, 
0.94-1.58) as seen in Table 5.5. However, the interaction term was not significant (p-
value=0.08). In stratified analysis by BMI, the hazards were similar across the three 
categories (i.e. normal/underweight, overweight, obese); (HR-1.37; 95%CI, 0.98-1.93 for 
the normal/underweight group, HR-1.27; 95%CI, 1.02-1.58 for the overweight group and 
HR-1.34; 95%CI, 1.07-1.67) (Table 5.6).  Similar results were seen when analyzed with 
the sample including dietary data (Table 5.7). Sensitivity analysis done after removal of 
participants with a person-time of a) ≤1 year, and b) ≤2years, did not suggest any change 
in the hazards ratio (HR-1.30, 1.31 respectively).  Similarly, the sensitivity analysis 
conducted for physical activity suggested no changes in the estimates.  
Discussion 
In our study we found an elevated risk of CRC among people with diabetes 
compared to people without diabetes. After adjusting for screening, gender, race, 
employment, education, age, family history of CRC, aspirin intake and cigarette smoking 
the risk of CRC was 40% higher among people with diabetes. Additionally adjusting for 
DII and physical activity, the risk was 33% higher. The results are consistent with the 




Most of the past literature suggests a positive association between diabetes and CRC. 
However some of studies investigating the all-site cancer risk and cancer subtypes, found 
no significant association between CRC and diabetes (206). Previous studies have shown 
inconsistency in results between males and females.. Studies by Diaz et al., J He et al. 
and Nilsen et al. show a higher risk among females (61, 124, 205). Diaz et al. in his study 
among a Hispanic population also showed that women had a higher risk of colon cancer 
(CC) while no significant association between T2DM and CC were found. In their study, 
Magliano et al. found a 36% increased risk of CRC among men (60). The estimates are 
also similar across most of these studies (ranging from 1.3-1.5). However, a lot of the 
studies could not adjust for some important confounders (only adjusted for age, BMI) 
(28-40, 42, 61, 76, 206) . 
As mentioned earlier hyperinsulinemia is one of major mechanisms in the 
association between diabetes and CRC. The simultaneous existence of common risk 
factors like unhealthy dietary habits, lack of physical activity, obesity, contributes 
towards insulin resistance and hyperinsulinemia. These factors lead to activation of IGF-I 
promoting carcinogenesis (28, 75, 82-84).  
As detection bias is suggested to be one of the explanations for the positive 
association between diabetes and colorectal cancer, we checked the association including 
screening as one of the covariates. After adjusting for screening, the association still 
existed. Besides that on stratification by the screening arm, an elevated risk was detected 
in both groups; however the association was only significant in the control group. 
Additionally, the distribution of screening was similar across the people with diabetes 




We adjusted for all the available potential confounders. From the crude model, the 
estimates were slightly attenuated, however he important covariates; there was an 
increased risk of CRC among people with diabetes. As a measurement of diet and 
inflammation through diet, we adjusted for DII. We observed a little difference between 
the model with and without DII. Most of the previous studies have adjusted for BMI. In 
our adjusted model, BMI showed no significance with CRC risk, in consistence with 
some of the  some of the previous studies (42, 61).  
Obesity is considered one of the major risk factors in this association; we also 
conducted a stratified analysis by BMI. Irrespective of the BMI group, people with 
diabetes still had a higher risk of CRC. Significant elevated risk were seen in 
normal/underweight and obese group. Our findings suggest that BMI might not be the 
only driving force in the association between diabetes and CRC. The results are similar to 
the study conducted by Seow et al. among Chinese population residing in Singapore (42).   
We conducted sensitivity analysis, excluding participants detected with CRC within two 
years of recruitment in the study. We still found the same results as in the final adjusted 
models.  
There are a few limitations to our study. Diabetes was self-reported which might 
lead to misclassification. However past literature suggests that self-report data regarding 
the chronic diseases is mostly accurate (228, 229). We could not account for diabetes 
medication due to lack of data. Apart from this, it is a longitudinal study with a large 
database. It had information on a lot of potential confounders that we considered in our 




impact of BMI on the association between diabetes and CRC. This is the first study to 
include DII while determining this important association, as inflammation is one of the 
suggested pathways in the association.   
Our study strengthens the existing results on the association between diabetes and 
CRC. However in addition to hyperinsulinemia, other mechanisms need to be explored in 







5874 with missing diabetes information – 
deleted  
30 with baseline cancer - deleted  
2075 participants with missing 
employment, education, F/H, cigarette 
smoking, aspirin intake were deleted  
576 and 700 participants were deleted 
with unconfirmed cancer status and 
person-time= 0 respectively  
31,625 participants with missing diet 













Table 5.1: Descriptive statistics of the PLCO population by diabetes status 
 
Diabetes Status   
  
Yes (%)   
N= 7,898 
No (%)  
N=106119 
p-values 
Sex       
 Male 57.0 47.5 
<.0001 
 Female 43.0 52.5 
Randomization Arm     
 Intervention 50.8 51.4 
0.2782 
 Control 49.2 48.6 
Race     
Non- Hispanic White 81.7 91.3 
<.0001 Non- Hispanic Black 8.7 3.2 
Others 9.6 5.5 
Age group     
70-80 years 16.6 12.6 
<.0001 60-70 years 56.9 53.3 
less then 60 years 26.5 34.1 
Education     
college grad and more  28.8 36.2 
<.0001 post high school, some college  36.1 34.4 




Employed 29.4 40.2 
<.0001 
Retired 52.2 43.1 
Unemployed 11.0 12.8 
Others 7.3 3.9 
Body Mass Index (kg/m
2
)     
Obese 44.5 21.8 
<.0001 
Overweight 37.7 42.4 
Normal 16.0 33.8 
Underweight 0.3 0.7 
Unknown 1.5 1.2 
Cigarette Smoking Status     
Current Cigarette Smoker 8.0 9.6 
<.0001 Former Cigarette Smoker 48.9 42.6 
Never Smoked Cigarettes 43.1 47.8 
Family History of Colorectal Cancer     
Yes, Immediate Family Member 9.6 10.3 
<.0001 
Possibly - Relative Or Cancer Type Not 
Clear 
3.3 2.5 





Diabetes Status   
  
Yes (%)   
N= 7,898 
No (%)  
N=106119 
p-values 
    
Aspirin Intake      
2+/day 6.1 5.2 
<.0001 
1/day 32.0 19.9 
1-4/month 9.4 13.4 
<4/month 8.1 9.8 






Table 5.2: Unadjusted HR (95%CI) for CRC by diabetes 
 
HR (95% CI) 
Diabetes (Yes)     






Table 5.3: Adjusted model with HR (95%CI) for CRC by diabetes  
  HR (95% CI) 
Diabetes (yes vs no) 1.40 (1.22,1.61) 
Randomization Arm (intervention vs control) 1.29 (1.19,1.41) 
Sex (female vs male) 0.69 (0.62,0.76) 
Race ( non-Hispanic black vs non-Hispanic white) 1.22 (1.02,1.45) 
Race ( others vs non-Hispanic white) 0.85 (0.71,1.02) 
Employment (others vs employed) 1.04 (0.84,1.29) 
Employment (retired vs employed) 1.06 (0.96,1.18) 
Employment (unknown vs employed) 1.10 (0.94,1.29) 
Education (college and more vs less than high school) 0.82 (0.73,0.91) 
Education (post high school/some college vs less than 
high school) 
0.90 (0.82,1.00) 
Age group ( 60-70 years vs <60 years) 1.74 (1.55,1.95) 
Age group ( 70-80 years vs <60 years) 2.41 (2.07,2.79) 
Family history (possibly vs no) 1.41 (1.14,1.75) 
Family history (yes vs no) 1.30 (1.14,1.48) 
Aspirin intake (1-4/week vs none) 0.79 (0.69,0.91) 
Aspirin intake (1/day vs none) 0.82 (0.73,0.92) 
Aspirin intake (>2/day vs none) 0.81 (0.66,0.99) 
Aspirin intake (<4/month vs none) 1.04 (0.91,1.20) 
Cigarette smoking (current smoker vs non-smoker) 1.43 (1.24,1.64) 
Cigarette smoking (past smoker vs non-smoker) 1.13 (1.03,1.23) 





Table 5.4: Adjusted model with HR (95%CI) for CRC by diabetes  
 
  HR 95%CI 
Diabetes (yes vs no) 1.33 (1.12,1.57) 
Gender (female vs male) 0.73 (0.65,0.81) 
BMI (unknown vs normal) 1.49 (1.04,2.13) 
BMI (obese vs normal) 1.10 (0.96,1.27) 
BMI (overweight vs normal) 1.06 (0.95,1.20) 
BMI (underweight vs normal) 0.73 (0.34,1.53) 
Screening Arm (Intervention vs control) 1.34 (1.22,1.48) 
Race ( non-Hispanic black vs non-Hispanic white) 1.23 (0.97,1.55) 
Race ( others vs non-Hispanic white) 0.83 (0.67,1.04) 
Education (college and more vs less than high school) 0.86 (0.76,0.97) 




Family history (possibly vs no) 1.43 (1.11,1.83) 
Family history (yes vs no) 1.28 (1.10,1.48) 
Aspirin intake (1-4/week vs none) 0.83 (0.71,0.97) 
Aspirin intake (1/day vs none) 0.84 (0.74,0.96) 
Aspirin intake (>2/day vs none) 0.77 (0.60,0.97) 
Aspirin intake (<4/month vs none) 1.08 (0.92,1.27) 
Cigarette smoking (current smoker vs non-smoker) 1.25 (1.06,1.49) 
Cigarette smoking (past smoker vs non-smoker) 1.09 (0.98,1.21) 
Physical Activity (yes vs no) 0.772 (0.64,0.92) 
Physical Activity (unknown vs no) 1.248 (1.04,1.50) 
Dietary Inflammatory Index (tertile 1 vs tertile 0) 1.05 (0.96,1.18) 
Dietary Inflammatory Index (tertile 2 vs tertile 0) 1.092 (0.96,1.24) 





Table 5.5: HR (95% CI) for CRC in relation to diabetes stratified by screening arm  
  HR (95% CI) 
  Intervention Control 
Diabetes (yes vs no) 1.22 (0.94,1.58) 1.41 (1.13,1.76) 
Gender (female vs male) 0.80 (0.68,0.94) 0.67 (0.58,0.78) 
BMI (unknown vs normal) 1.60 (0.89,2.87) 1.43 (0.91,2.26) 
BMI (obese vs normal) 1.06 (0.87,1.31) 1.13 (0.94,1.36) 
BMI (overweight vs normal) 1.03 (0.87,1.24) 1.09 (0.93,1.28) 
BMI (underweight vs normal) 0.45 (0.11,1.82) 0.95 (0.39,2.31) 
Race ( non-Hispanic black vs non-
Hispanic white) 
1.55 (1.13,2.12) 0.97 (0.69,1.38) 
Race ( others vs non-Hispanic white) 0.83 (0.58,1.17) 0.84 (0.63,1.12) 
Education (college and more vs less 
than high school) 
0.84 (0.70,1.02) 0.87 (0.73,1.03) 
Education (post high school/some 
college vs less than high school) 
0.98 (0.82,1.17) 0.97 (0.83,1.14) 
Family history (possibly vs no) 1.17 (0.78,1.75) 1.66 (1.21,2.28) 
Family history (yes vs no) 1.23 (0.98,1.54) 1.31 (1.08,1.60) 
Aspirin intake (1-4/week vs none) 0.93 (0.73,1.17) 0.76 (0.61,0.95) 
Aspirin intake (1/day vs none) 1.00 (0.83,1.21) 0.72 (0.61,0.87) 
Aspirin intake (>2/day vs none) 0.85 (0.60,1.21) 0.70 (0.51,0.98) 
Aspirin intake (<4/month vs none) 1.07 (0.82,1.38) 1.09 (0.88,1.34) 
Cigarette smoking (current smoker 
vs non-smoker) 
1.24 (0.96,1.61) 1.27 (1.01,1.59) 
Cigarette smoking (past smoker vs 
non-smoker) 
1.10 (0.93,1.29) 1.09 (0.94,1.25) 
Physical Activity (yes vs no) 0.75 (0.57,0.98) 0.79 (0.62,1.01) 
Physical Activity (unknown vs no) 1.35 (1.02,1.77) 1.18 (0.92,1.50) 
Dietary Inflammatory Index (pro-
inflammatory vs anti-inflammatory) 
1.04 (0.90,1.21) 1.09 (0.95,1.25) 









Table 5.6: Adjusted model with HR (95%CI), stratified by BMI  
VARIABLES 
 NORMAL / 
UNDERWEIGHT OVERWEIGHT OBESE 
Diabetes (yes vs no) 1.38 (0.98,1.93) 1.27 (1.02,1.58) 1.34 (1.07,1.67) 
Gender (female vs male) 0.72 (0.62,0.85) 0.71 (0.62,0.82) 0.69 (0.57,0.82) 
Randomization Arm (intervention vs control) 1.28 (1.09,1.49) 1.35 (1.18,1.53) 1.19 (1.01,1.41) 
Race ( non-Hispanic black vs non-Hispanic white) 1.04 (0.71,1.53) 1.15 (0.87,1.52) 1.02 (0.75,1.39) 
Race ( others vs non-Hispanic white) 0.72 (0.53,0.97) 0.90 (0.68,1.18) 0.77 (0.48,1.23) 
Education (college and more vs less than high 
school) 
0.73 (0.60,0.89) 0.94 (0.80,1.10) 0.96 (0.77,1.20) 
Education (post high school/some college vs less 
than high school) 
0.91 (0.76,1.10) 0.88 (0.75,1.03) 1.02 (0.84,1.24) 
Family history (possibly vs no) 1.71 (1.18,2.48) 1.17 (0.83,1.65) 1.41 (0.92,2.14) 
Family history (yes vs no) 1.06 (0.82,1.37) 1.34 (1.10,1.62) 1.53 (1.20,1.95) 
Aspirin intake (1-4/week vs none) 0.84 (0.65,1.07) 0.76 (0.62,0.94) 0.89 (0.67,1.19) 
Aspirin intake (1/day vs none) 0.71 (0.57,0.89) 0.80 (0.68,0.95) 0.89 (0.71,1.1) 
Aspirin intake (>2/day vs none) 0.76 (0.51,1.13) 0.82 (0.61,1.12) 0.82 (0.57,1.18) 
Aspirin intake (<4/month vs none) 1.16 (0.90,1.48) 0.93 (0.75,1.16) 1.15 (0.87,1.52) 
Cigarette smoking (current smoker vs non-smoker) 1.36 (1.08,1.72) 1.17 (0.93,1.47) 1.53 (1.13,2.07) 
Cigarette smoking (past smoker vs non-smoker) 1.14 (0.96,1.36) 1.11 (0.96,1.27) 1.16 (0.96,1.39) 
Physical Activity (yes vs no) 0.82 (0.58,1.16) 0.77 (0.59,1.00) 0.65 (0.49,0.85) 
Physical Activity (unknown vs no) 1.47 (1.05,2.08) 1.36 (1.04,1.76) 1.03 (0.79,1.35) 
Age group ( 60-70 years vs <60 years) 1.80 (1.46,2.22) 1.69 (1.43,2.00) 1.75 (1.43,2.15) 









Table 5.7: Adjusted model with HR (95%CI), stratified by BMI including diet data 
  N=37915 N= 47962 N=26716 
  
NORMAL/ 
UNDERWEIGHT OVERWEIGHT OBESE 
Diabetes (yes vs no) 1.74 (1.20,2.53) 1.25 (0.95,1.64) 1.44 (1.11,1.87) 
Gender (female vs male) 0.83 (0.69,1.01) 0.77 (0.65,0.90) 0.71 (0.57,0.88) 
Randomization Arm (intervention vs 
control) 
1.30 (1.09,1.56) 1.39 (1.20,1.61) 1.38 (1.13,1.69) 
Race ( non-Hispanic black vs non-Hispanic 
white) 
1.85 (1.19,2.88) 1.44 (1.00,2.07) 0.99 (0.63,1.54) 
Race ( others vs non-Hispanic white) 0.83 (0.58,1.19) 1.00 (0.72,1.39) 0.85 (0.48,1.50) 
Family history (possibly vs no) 1.69 (1.08,2.66) 1.43 (0.98,2.09) 1.45 (0.88,2.40) 
Family history (yes vs no) 1.06 (0.79,1.41) 1.31 (1.05,1.64) 1.47 (1.10,1.96) 
Cigarette smoking (current smoker vs non-
smoker) 
1.24 (0.93,1.65) 1.26 (0.97,1.64) 1.72 (1.20,2.47) 
Cigarette smoking (past smoker vs non-
smoker) 
1.19 (0.98,1.44) 1.05 (0.90,1.23) 1.12 (0.90,1.38) 
Age group ( 60-70 years vs <60 years) 1.89 (1.48,2.40) 1.76 (1.46,2.13) 1.92 (1.51,2.45) 
Age group ( 70-80 years vs <60 years) 2.57 (1.93,3.42) 2.35 (1.85,2.98) 2.58 (1.85,3.60) 
DII (tertile 2 vs tertile 1)  0.96 (0.77,1.20) 1.06 (0.88,1.28) 1.28 (0.99,1.66) 
DII (tertile 3 vs tertile 1)  1.22 (0.97,1.54) 1.18 (0.97,1.43) 1.13 (0.86,1.48) 
# additionally deleted participants with missing BMI data. 
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DURATION OF DIABETES AND COLORECTAL CANCER INCIDENCE – IN A 
LONGITUDINAL STUDY  
Abstract 
Background: Diabetes has been shown to increase the risk of colorectal cancer (CRC). 
However, very few studies have assessed the association between duration of diabetes 
and either CRC risk or disease aggressiveness. Even more rarely have studies confirmed 
the status of type 2 diabetes mellitus (T2DM) while determining the diabetes-CRC 
association.  
Objective: We evaluated the association between duration of diabetes and cancer risk 
and cancer aggressiveness measured in terms of cancer grades and stage. 
Methods: Using data from the Prostate Lung Colorectal Ovarian Cancer Screening Trial 
(PLCO), we examined the impact of T2DM and diabetes duration on CRC risk, as well as 
grade and stage at diagnosis. Diabetes duration was calculated using information on age 
at diabetes diagnosis. CRC information was derived using annually administered 
questionnaires and confirmed using medical records. We fit a Cox proportional hazards 






Results: Participants with >10 years of diabetes had a higher risk (HR=1.37; 95%CI: 
1.06, 1.77) of CRC incidence compared people without diabetes. An apparently smaller 
effect was observed among people with <10 years of diabetes duration (HR=1.13; 
95%CI: 0.89, 1.43); however, it was not significant. We did not find significant results in 
the association between cancer aggressiveness and diabetes.   
Conclusion: CRC risk was higher among people with longer duration of diabetes, even 






Type 2 Diabetes Mellitus (T2DM) and cancer are both among the top 10 leading 
causes of mortality (1-3). Though to differing extents, both of these diseases can be 
prevented and controlled by appropriate healthy lifestyle and behavioral changes. These 
diseases also pose a problem towards the individual and nations’ health and economic 
burden (22, 52, 135).  
Apart from the commonly observed diabetic complications, T2DM has also been 
linked with several chronic diseases like cardiovascular diseases, cancer (60, 62, 63, 66, 
206, 220). Site/organ specific cancers have different associations with diabetes. Past 
literature suggest an increased risk of colorectal, liver, pancreatic and breast cancer 
among people with diabetes as compared to people without diabetes (29, 34, 36, 37, 39, 
42, 59, 61, 62, 64, 66, 193-196, 198, 203, 204, 220). In contrast, an inverse association is 
observed with prostate cancer risk (59, 201, 203, 207). Among these cancers, CRC has 
shown to be strongly associated with T2DM as evidenced in most of the past studies (28, 
29, 33, 34, 36, 37, 39, 42, 61, 76, 205). However very few studies have used information 
on diabetes duration when investigating the association between T2DM and CRC (33, 34, 
39, 77, 230). The existing results are inconsistent.    
With hyperinsulinemia, being considered to be one of the major underlying 
mechanisms, it becomes important to further investigate the association between duration 
of diabetes and CRC. Hyperinsulinemia mainly occurs in the initial stages of T2DM that 
might be followed by hypoinsulinemia due to destruction of the β cells of pancreas that 





of common risk factors like diet, physical activity and obesity. Over time, with longer 
duration of diabetes, there might be a change in these lifestyle factors.  
There is growing evidence of association between T2DM and CRC but lack of 
data on duration of diabetes. Considering the above factors, in our study, we will 
determine the association between T2DM duration and CRC incidence and CRC 
aggressiveness (cancer grade and stage) considering important potential confounders like 
diet (using dietary inflammatory index), physical activity and BMI.  
Methods  
For our third aim, we evaluated the association between duration of diabetes and 
colorectal cancer risk and colorectal cancer aggressiveness. We used the PLCO database 
for this purpose. The PLCO trial was conducted with the aim of understanding the impact 
of screening on early detection of cancer (182, 183). The overall sample consisted of 
154,897 participants and approximately 75,000 participants were in the intervention arm 
and control randomized on if they received screening or not. After applying the exclusion 
criteria, the final analytic dataset included 94,921 participants. A series of questionnaires 
were administered throughout the course of the study. The demographic, anthropometric 
and medical history information was collected from baseline and supplemental 
questionnaires. Diet information was collected twice during the course of the study- at 
baseline from the intervention arm and from 1998-2001 from both the screening arms. 
The enrollment was conducted from 1993-2001. The follow-up began in 2009 with a 
median follow-up time of 12.4 years. The main exclusion criteria considered were history 





besides basal-cell or squamous–cell skin cancer. Details of the study design and other 
criteria have been mentioned earlier (183).  
Main independent variable: Duration of diabetes 
The baseline (BQX) and supplemental (SQX) questionnaires were used to 
determine this variable. The BQX and SQX were administered at baseline and years 
2006-2008 respectively. BQX included the question “Did the participant ever have 
diabetes?” and the SQX used the question “Were you ever diagnosed with diabetes?”  
The SQX also included information on the age at diagnosis of diabetes with 4 categories 
(<50 years, 50-59years, 60-69years and >70years).  
Participants with missing information on diabetes in both BQX and SQX were 
deleted. The overall sample with a valid SQX consists of 103,758 participants. For the 
estimation of duration of diabetes variable, we included participants who mentioned yes 
for diabetes in the SQX. Among the participants who mentioned yes for diabetes in the 
SQX (N=13,675), 12,927 participants answered the question regarding the age at 
diagnosis. For the final calculation, we subtracted the mean of the range for the 50-59 
years (i.e., 54.5 years) and 60-69 years (i.e., 64.5 years) from the age of the participant 
when the SQX was answered. For the last category (>70 years), we will use the mean of 
70 years and the highest age of the participant during the SQX i.e. (87 years) (i.e. 78.5) 
and subtract it from the age of participant. Using this method, we get negative values for 
some of the participants for the calculated variable. As duration of diabetes cannot be less 
than 0, we convert these numbers to 1 (minimum possible value).  Figure1 gives the 





information the variable diabetes duration was categorized into ‘no diabetes’, 
‘<=10years’, and ‘>10years’.  
Main Dependent Variable: Colorectal Cancer (CRC) incidence, stage, and grade  
CRC incidence data were collected using Annual Study Update Questionnaire 
(ASU) administered annually. The incidence, stage and grade of CRC were confirmed 
using medical records. For the final analysis, participants with confirmed status of CRC 
(yes/no) were included. CRC grades I and II were combined and considered low grade 
while grade III and IV were grouped together as high grade. For determining CRC stage, 
we used information combining the clinical and pathologic stage of CRC and similar to 
grade, stage I and II were combined and stage III and IV were combined. Accordingly, 
the sample size was 1032 and 1073 for CRC grade and CRC stage as outcomes 
respectively.  
Statistical Analysis:   
Descriptive statistics (chi-sq for categorical and t-test for continuous variables) 
were calculated for participants by their diabetes duration. For CRC incidence, the 
following exclusion criteria were used. Participants with missing data on the variable 
‘age at diagnosis’ in the SQX, missing information on education, an invalid SQX were 
deleted. Person-years were calculated from the day of entry in the trial to CRC diagnosis, 
or last day of remaining free from cancer and/or death of the participant. Cox 
proportional hazard model was used to estimate hazards ratio and 95% Confidence 





We adjusted for age (when SQX was answered), race (non-Hispanic white, non-
Hispanic black and others), screening arm (intervention, control group), BMI (<25, 25–
29.9, and 30 kg/m
2 
and unknown), gender, employment status (employed, unemployed, 
retired and others), education (graduate and more, high school/some college, and less 
than high school), aspirin intake in past 12 months (≤1/week, ≥2/week, none, unknown), 
smoking status (current smoker, past smoker, non-smoker and unknown), family history 
of colorectal cancer (yes, no, missing) and DII (dietary inflammatory index) score, 
physical activity (active –yes, no, missing).DII is a tool measuring the inflammatory level 
of food. It is calculated using up to 45 food parameters, and based on availability of these 
parameters.  In our study it was based on 37 parameters, which is at the upper end of 
what is available from structured questionnaires such as food frequency questionnaires 
(FFQ). The details regarding DII have been provided elsewhere (188).  We checked the 
proportional hazards (PH)-assumptions for diabetes duration and other covariates. As 
BMI did not satisfy the PH-assumption, we conducted stratified analysis. Figure 2 
provides the final sample used for analysis (N= 83,904).  
For CRC stage and grade as the outcomes, the data were restricted to participants 
with information on stage and grade, respectively. Further, the people with missing data 
on aspirin intake and cigarette smoking were deleted. Logistic regression was used to 
estimate odds ratio (OR) and 95% confidence interval (CI) for CRC stage and grade by 
duration of diabetes. 
Sensitivity analysis was conducted, deleting participants with diagnosis of CRC 






The participants in the diabetes (including both groups with diabetes i.e. >10 and 
<=10 years duration) group are significantly different in their characteristics from those 
without diabetes. More than 50% of participants in the diabetic group are males. 
Compared to people without diabetes, people with diabetes had a lower proportion of 
Non-Hispanic Whites (92% vs. 88% and 85.6%). More than 75% of diabetic participants 
are either obese or overweight. A majority of the participants were retired. Around 5% of 
participants were current smokers and more than 75% of participants did not have a 
family history of CRC. However, the distribution of the screening arm was similar across 
the diabetic and non diabetic groups (Table 6.1).  
The crude model estimated higher hazards of CRC among both the diabetic 
groups compared to people without diabetes (HR=1.69; 95%CI=1.34, 2.13 among the > 
10 years of duration and HR=1.27, 95%CI=1.03, 1.56 among ≤10years of duration).  The 
adjusted HR was 1.37 (95%CI=1.06, 1.77) among participants with >10 years of diabetes 
and 1.13 (95%CI=0.89, 1.42) with diabetes ≤10 years of diabetes compared to people 
without diabetes. Males had a higher risk of CRC compared to females (HR=1.45; 
95%CI=1.25, 1.69) (Table 6.2).  
The results of the adjusted model for cancer aggressiveness (grade and stage) are 
shown in Table 6.3. No significant association was detected between diabetes duration 
and cancer aggressiveness. In the adjusted model, the hazards of higher cancer stage (III 
and IV) was 0.79 (95%CI=0.45, 1.38) among people with >10 years of diabetes and 1.12 





seen for cancer grades (Table 6.4). The results remained same, after conducting 
sensitivity analysis. 
Discussion 
In our study, we evaluated the association between duration of diabetes and 
colorectal cancer incidence and cancer stage and grade. Our findings suggest an increased 
risk of CRC among participants with longest duration compared to people without 
diabetes.  Participants with >10 years of diabetes duration had a 37% higher risk while 
participants with <=10 years of diabetes duration appeared to have a 13% higher risk 
compared to participants without diabetes. We found contrasting results in our study 
compared to previous study results; however the duration ranges are different across 
studies (34).  
Substantial evidence exists assessing the association between diabetes and CRC 
and have demonstrated an increased risk among people with diabetes. However, very few 
studies have checked the role of diabetes duration in in this regards. Currie et al. and 
Yang et al. in their studies, adjusted for diabetes duration when evaluating the association 
between diabetes and cancer. These studies lacked  information on diet and physical 
activity (77, 230).  In a Swedish study, a 39% elevated incidence of colon cancer was 
observed among people with diabetes, unaffected by duration of diabetes, age or gender. 
In the study conducted by Flood et al, in the US, the results showed that participants with 
moderate duration had a higher risk and people with longer duration had a lower risk as 
compared to participants without diabetes. Participants with diabetes diagnosis between 





12 years had a lower non-significant association with CRC risk (33). Hu et al. in their 
study also showed similar result among participants with moderate duration of diabetes 
(11-15 years) having a higher risk of colorectal cancer compared to people without 
diabetes. While those with duration of >15years had a lower risk of CRC (34).  
 Hyperinsulinemia is considered as the major reason leading to this association. 
Common risk factors like lack of physical activity, unhealthy diet and obesity contribute 
towards insulin resistance and hyperinsulinemia. Hyperinsulinemia leads to activation of 
IGF-I. As insulin and IGF-I act a growth promoter and inhibitor of apoptosis; it helps in 
carcinogenesis in colonic epithelium. However, in the later stages of diabetes the β cells 
of pancreas are unable to compensate for the insulin production leading to 
hypoinsulinemia. However inflammation could lead to the association for longer duration 
of diabetes and increased risk of CRC. Persistence of unhealthy lifestyle factors and 
longer duration of diabetes can lead to inflammation. Apart from this, there can be a 
change in the intake of diabetic medications. As seen from the past literature, diabetic 
medications are also associated with CRC risk (43, 78, 80, 81, 84, 93, 95, 99, 230-232).   
We did not find any significant association with CRC stage and grade. The 
direction of association was higher among people with shorter duration of diabetes as 
compared to those with longer duration of diabetes.  
However our study did not have information on diabetic medication. The sample 
size for cancer grade and stage was reduced because of the missing data. With all the 
limitations, our study, we could determine and confirm the T2DM diabetes status for the 





report questionnaire data. These self-report data regarding chronic diseases are usually 
accurate (225-227). Except for medication data, we adjusted for physical activity, 
obesity, family history of CRC and others that can affect the association between diabetes 
and CRC. Thus our results are strengthened by adjusting for these confounders. Ours is 
the first study to adjust for inflammation caused due to diet that has been related to cancer 
and diabetes. No changes were observed in sensitivity analysis. 
To conclude, in our study, we detected an association between duration of 
diabetes and CRC incidence. For future studies, we can replicate these studies with data 
consisting information on diabetic medications. It is also important to check the severity 











SQX  (N=103,758) Age of diagnosis  (N=12,927 after excluding the missing values) 
      
   <50 years  1315 Deleted  
   50-59 years  2186  
 Yes  5355 60-69 years  1364  Used for calculation of 
duration 
Yes (11,529)   >70 years 195  
 No 300 Missing  295  
 Missing  191    
      
      
      
   <50 years  143 Deleted  
 Yes 7948 50-59 years  1214  
No (137494)   60-69 years  3977  Used for calculation of 
duration 
 No 83,533 >70 years 2180  
 Missing  3940 Missing  434  
      
      
      
   <50 years  43 Deleted  
 Yes 372 50-59 years  86  
Missing 
(5874) 
  60-69 years  170  Used for calculation of 
duration 
 No 2119 >70 years 54  
 Missing  0 Missing 19  
      
  







(N = 154,897)  
Supplemental Questionnaire 
(SQX) 
(N = 103,873) with valid SQX
  





(N = 97,378)  
Participants with CRC status (yes/no) 
were included. Participants with 
baseline cancer were deleted. 
Overall (N= 335) were deleted.   
N = 
97,043 
Participants with missing diet and 




Figure 6.2: Consort diagram for final analytic dataset, PLCO, 1993 to 2009 
 
82 
Table 6.1: Descriptive statistics by diabetes duration, PLCO, 1993 to 2009  
 
Diabetes duration   
  no diabetes 0-10 years >10years p-
values    (N=83819) (N=7050) (N=4052) 
Sex         
 Male 45.5 54.9 62.2 
<.0001 
 Female 54.5 45.1 37.8 
 
   
  
Randomization Arm   
 Intervention 51.2 51.8 52.4 
0.23 
 Control 48.8 48.2 47.6 
Race      
Non- Hispanic White 92.3 88.0 85.6 
<.0001 Non- Hispanic Black 2.6 5.2 6.2 
Others 5.1 6.8 8.2 
Education      
college grad and more  39.4 32.0 32.0 
<.0001 post high school, some college  34.0 37.0 34.8 
less than high school 26.6 31.0 33.2 
Employment 
   
  
Employed 17.8 15.2 9.5 
<.0001 
Retired 62.2 65.1 73.9 
Unemployed 8.8 7.0 6.2 
Others 1.7 2.9 1.3 
Missing 9.5 9.8 9.1 
Body Mass Index (kg/m
2
)      
Obese 20.5 43.8 42.4 
<.0001 
Overweight 40.6 36.2 36.6 
Normal 33.9 15.0 15.9 
Underweight 1.0 0.4 0.4 
Unknown 4.0 4.6 4.7 
Cigarette Smoking Status      
Current Cigarette Smoker 6.5 6.1 5.3 
<.0001 
Former Cigarette Smoker 45.4 50.8 51.5 
Never Smoked Cigarettes 46.7 41.7 41.5 
Missing 1.4 1.4 1.7 
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Family History of Colorectal 
Cancer 
   
  
Yes 10.5 10.6 9.0 
<.001 No 77.3 76.5 77.4 
Missing 12.2 12.9 13.6 
Aspirin Intake (at least 1/week)     
More than 20 years  6.6 8.1 8.1 
<.0001 
Less than 20 years  47.2 59.2 61.3 
Less than 1/week 21.7 14.0 12.9 
None 22.4 16.7 15.1 
Missing 2.0 2.0 2.6 
  Mean (±std) 
 Age (years) 71.1 (±5.9) 70.9 (±5.8) 73.5 (±5.3) <.0001 





Table 6.2: HR (95%CI) for CRC incidence by diabetes duration, PLCO, 1993 to 2009   
CRUDE MODEL   
 HR  95%CI 
diabetes duration   > 10 years vs no diabetes 1.69 (1.34, 2.13) 
<=10 years vs no diabetes 1.27 (1.03,1.56) 
   
ADJUSTED MODEL   
diabetes duration   >10 years vs no diabetes 1.37 (1.06,1.77) 
<=10 years vs no diabetes 1.13 (0.89,1.42) 
# adjusted for gender, age, screening arm, employment status, race, education, aspirin 
use, smoking status, family history of CRC, DII and physical activity 
 
 
Table 6.3: OR (95%CI) for cancer aggressiveness – stage by duration of diabetes 
  OR 95% CI 
Diabetes duration    > 10 YEARS vs no diabetes 0.79 (0.46,1.38) 
      <= 10 YEARS vs no diabetes 1.12 (0.71,1.78) 
  
Table 6.4: OR (95%CI) for cancer aggressiveness – grade by duration of diabetes 
  OR 95% CI 
Diabetes duration    > 10 YEARS vs no diabetes 0.73 (0.37,1.46) 
                           <= 10 YEARS vs no diabetes 0.94 (0.54,1.70) 
# Models adjusted for gender, intervention arm, race, education, BMI, age, aspirin-intake, 






We conducted this study with the aim of understanding the association between 
diabetes and cancer. A lot of previous studies have evaluated this association. However 
most of these studies are conducted in the western world (developed world). None of 
these studies were conducted in India. Therefore we began studying this association in an 
Indian population. Diabetes is fast gaining the status of an epidemic in India. 
Additionally, with the current stage of economic, nutritional and epidemiologic transition 
phase, it becomes even more important to understand this association in India. Besides 
this, the existing literature in the developed countries has mentioned a probability of 
detection bias as being one of the reasons in the association. Through our second question 
we evaluated this association in a longitudinal screening trial conducted in the US 
population, considering all the important available potential confounders. With our third 
aim we tried to determine the association between diabetes duration and CRC cancer 
incidence and aggressiveness. 
Process of working on dissertation 
To begin the dissertation process, my advisor Dr. Hebert, guided and suggested 
me to use the Mumbai Cohort Study. This study was started in Mumbai in 1993 and Dr. 
Hebert was one of the Co-PIs. We initially aimed as assessing the role of diabetes and 
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CRC incidence in MCS. However, due to the extremely small sample size of the 
incident cases, we decided to change the question and determine the association with 
cancer incidence. For the US study we used the Prostate Lung Colorectal Ovarian 
screening trial (PLCO). The PLCO questionnaires included all the important covariates 
and medical history information that we needed for our analysis. It also included 
information on the age at diagnosis of diabetes in of the questionnaires that would be 
helpful for our third analysis.   
Problems faced and things learnt along the way 
Although both these databases are longitudinal studies with a huge overall sample 
sizes, there were some common data cleaning problems that we faced in the process of 
getting the final datasets ready for our analysis. The MCS had a lot of missing data for 
our main exposure variable i.e. diabetes. Besides this, it took some time to come to a 
conclusion regarding variable coding, addressing missing data etc. However while going 
through this process, all my committee members helped me in coming to the correct 
decision for our study. Additionally as the missing diabetes data was a lot, we thought of 
conducting some data manipulation for this data separately and performing a separate 
analysis for that particular data. Following a committee meeting, we decided to utilize 
this data in another way by using predicted probabilities method as suggested by Dr. 
Zhang and agreed by the committee.  
Following this, I started working on the PLCO data. We had similar questions for 
this study regarding the missing data and fixing the inclusion/ exclusion criteria. 
Following this the most difficult part of the third question was the calculation of the 
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diabetes duration variable. We had information on the age at diabetes diagnosis, however 
it was a (range) categorical variable. Some of the data did not add up to the final 
numbers. With Dr. Liese and Dr. Hebert’s ideas and suggestions, we were finally able to 
derive the variable duration of diabetes.  
We also aimed at understanding the role of dietary inflammatory index in this 
association as inflammation is one of suggested underlying process leading to the 
association between diabetes and cancer. However this data was only available in the 
PLCO data. To utilize the DII data more appropriately, we need to conduct further 
detailed analysis and determine its role in the association. This will be one of the 
questions I would like to address in details for future analysis. Additionally, we will 
replicate the data using other databases consisting of the medical history data too. Using 
the available information we finally completed our analysis.   
Things learnt 
Initially, I had a lot of anxiety in meeting with my committee members. Slowly, I 
developed confidence in my work and started having regular meeting with my professors. 
In my weekly meeting with Dr. Hebert, again slowly but eventually, I learnt new things 
and got new ideas regarding not only my PhD process but my future goals too. One thing 
that I worked on and am still in the process of working on is being assertive and 
managing time properly as guided by Dr. Hebert.  
In my experience every time I had problem with the data or with the analysis, it 
took me time to restart the process. Therefore it is very important to stay encouraged, as it 
is very simple to get discouraged that’s slows down the process. 
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PhD is a learning process and it also needs a lot of patience and that is definitely 
one of the other things I have developed over time. I have started being less anxious and 
stressed out and being more focused and positive about the work I do. My advisor helped 
me in thinking clearly and supported me throughout the process. Additionally my other 
committee members also encouraged me throughout my dissertation work.  
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